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RIN    RNA intergrity number 
RMA    Robust Multi-array average 
RNA     Ribonucleic acid  
RNAi     RNA-mediated interference  
rpm     revolutions per minute 
RPMI 1640   Roswell Park Memorial Institute     
RT     Room temperature  
SAPE     Streptavidin-Phycoerythrin  
SCR     Short consensuses repeat  
SCRs     Short consensus repeats’ 
SD      Standard deviation 
SDS-PAGE    Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis  
SF3B1    Splicing factor 3B subunit 1  
Smad     Suppressor of Mothers Against Decapentaplegic  
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SSC    Side scatter dot plots 
STAT    Signal Transducer And Activator Of Transcription 
Stds     Standards   
Tconv     Conventional T-cells  
TCR     T-cell receptor  
TET2     Ten-Eleven Translocation-2   
TGF-β    Transforming growth factor beta 
TGFbRII     Transforming growth factor beta receptor II 
Th1, Th2, Th9, Th17  T-helper cells 
TLR4    Toll-like receptor 4  
tMDS     Therapy-related MDS  
TNF-alpha   Tumor necrosis factor-alpha  
TP53    Tumour protein 53  
Tr1    T regulatory type 1 cells  
Tregs    Regulatory T-cells 
TREM-1   Triggering receptor expressed on myeloid cells 1  
UAB     Universal Assay Buffer 
USA    United State Of America  
V     Variable 
VEGF     Vascular endothelial growth factor 
WB     Western blot  
WHO     World Health Organisation   
WR     Working reagent  
WDR3    WD repeat-containing protein 3  






Myelodysplastic syndrome (MDS) is a relatively uncommon clonal haematological disease 
that is characterised by peripheral blood cytopenias despite a normal or hypercellular bone 
marrow. The disease transforms to acute myeloid leukaemia in up to 40% of cases. Several 
studies have established that the T-cell mediated immune dysregulation is an important feature 
of MDS. Low risk MDS is associated with a pro-inflammatory environment and an increase in 
IL-17 producing T-cells as well as an increase in the serum IL-17, IL-12, RANTES and IFN-γ. 
In contrast, IL-10 (inhibitory factor) and IL-2R (soluble receptor) are increased in high risk 
MDS. A high number of IL-17 producing CD4
+
 T-cells are found in low-risk MDS compared 
to the high-risk disease where expansion of T regulatory cells (Tregs) is the main feature. 
However, the mechanism for this switch in the immune signature is not fully understood. 
Immune cell derived complement activation fragments are recently identified as key players in 
driving and modulating adaptive immunity, C3a and C3b. C3 fragments C3a and C5a are 
particularly important in induction of IFN-γ secretion through autocrine engagement of the 
C3a receptor and CD46 (C3b receptor). The activation pathway following CD46 activation 
varies between Tconv and Tregs and the balance between these pathways is crucial for the 
Treg/Tconv equilibrium. The objective of this project was to elucidate the role of intracellular 
complement components (C3a and C5a), regulators (CD46) and their receptors (C3aR, C5aR1 
and C5aR2) in the expansion of T regulatory cells, which is one of the main factors in the 
progression of high-risk MDS patients towards AML. In conclusion, this work shows for the 
first time the potential role of complement in CD4
+
 T-cells polarisation in MDS patients and 
provides data on three major pathways that may be implicated in the lack of complement in T-
cells of MDS patients. Future work to explore these further may help to identify potential 




Chapter 1: Introduction 
I. Myelodysplastic Syndrome (MDS) 
 
1.1 Myelodysplastic syndrome (MDS) 
Bone marrow failure syndrome consists of a number of overlapping diseases that can either be 
acquired or inherited. These conditions affect the haematopoietic stem cells and are 
characterized by variable peripheral blood cytopenias, dysplasia involving either one or 
multiple cell lines, ineffective haematopoiesis, and often an increased risk of transformation to 
acute myeloid leukaemia ((Bennett et al., 1982, Vardiman, 2003) (Zeidan et al., 2017)). 
However, lymphoid lineages are often spared. While Diamond-Blackfan anaemia, Fanconi 
anaemia, telomeropathies such as dyskeratosis congenita (DKC) and other genetic disorders 
are inherited bone marrow failure syndromes, idiopathic aplastic anaemia is acquired and is the 
most frequent cause of acquired bone marrow failure (Kai et al., 2016). Other conditions with 
presentations similar to acquired bone marrow failure include large granular lymphocytic 
(LGL) leukaemia, paroxysmal nocturnal haemoglobinuria (PNH), and myelodysplastic 
syndrome (MDS) (DeZern and Sekeres, 2014).  
MDS is a clonal haematological disease that is characterised by peripheral blood cytopenias 
despite a normal or hypercellular bone marrow. MDS can transform to acute myeloid 
leukaemia in up to 40% of cases ((Vardiman, 2003);(Yoshizato and Makishima, 2016). The 
prevalence of MDS is approximately 2 to 12 per 100,000 annually. Prevalence increases with 
age to 30-50-cases amongst subjects aged 70 years or above (Rollison et al., 2008).  
Given the aging populations particularly in the developed countries, MDS is likely to pose a 
major health challenge.  Several lines of evidence have established that MDS is a stem cell 
disease. Driver mutations in the stem cells lead to a growth advantage for the clone with a 
marked reduction in the differentiation potential, leading to hypercellular bone marrow, 
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increased apoptosis of bone marrow haemopoeitic cells and a consequent peripheral blood 
cytopenias (Corey et al., 2007, Gattermann et al., 2008, Mian et al., 2015). 
A specific subset of MDS, referred to as therapy-related MDS (tMDS), can develop following 
previous chemotherapy and/or radiotherapy exposure, with peak incidence often between 2-4 
years after the first exposure (Raposa and Varkonyi, 1987). About 30% of MDS refers to 
primary MDS. tMDS subset is a more aggressive form of the disease with rapid progression to 
often chemo-resistant AML and poor survival (Rau et al., 2012). A common characteristic of 
both MDS and AML is ineffective haematopoiesis, often linked to genetic lesions (Nimer, 
2006). A broad range of mutations affecting several genes contributes to the heterogeneity of 
the disease making its pathophysiology relatively complex (Galili et al., 2009).  In addition, 
abnormalities in innate and adaptive immunity are important in defective immune surveillance, 
immune tolerance and subversion. Collectively these abnormalities allow the unrestricted 
proliferation of the dysplastic clones (Voulgarelis et al., 2004). To this end it is interesting to 
note that several studies have documented the association of MDS with several autoimmune 
diseases, such as seronegative arthritis (Castro et al., 1991, Chandran et al., 1996, Saif et al., 
2002), inflammatory bowel disease, scleroderma, chondritis and sweets syndrome (Saif et al., 
2002, Hu et al., 2014), among many others (Saif et al., 2002, Billstrom et al., 1995). Poor 
survival is often reported in MDS patients in association with autoimmunity (Saif et al., 2002). 
1.2 Historical Context of MDS 
The story of MDS goes back to 1898 (M.Lowenthal, 2011, Layton and Mufti, 1986). MDS was 
first acknowledged in the early 1900s, but the usage of the term MDS became prominent in 
1976 when the French American British (FAB) morphology group used the term to distinguish 
this group of relatively chronic haematological diseases from acute myeloid leukaemia (Table 
1-1) (Bennett et al., 1976). In 1900, Leube described a patient with severe megaloblastic 
anaemia, followed by the development of overt leukaemia. This was followed by similar 
reports of patients characterized by cytopenia, dysmaturation of marrow precursors, increase in 
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marrow blasts, and significant risk of development to acute myeloid leukaemia (Hellstrom-
Lindberg, 2008). Ernst Meumann (1834-1918) was attributed with the important discovery that 
bone marrow (BM) is the site of blood formation. During the same era, the first description of 
the various blood cells and their morphology was made by a German scientist/physician Paul 
Ehrlich (1879) (Lowenthal, 2011). Soon after, in 1923, Giovanni Di Guglielmo, a physician in 
Naples, Italy, reported a number of bone marrow disorders attributed to bizarrely-shaped red 
blood cells that resulted in low blood count, in particular anaemia, which in some cases proved 
fatal in the long term (Steensma, 2011).  For a long time, all the bone marrow disorders 
associated with anaemia and abnormal-appearing cells were known en masse as “Di Guglielmo 
Syndrome” by doctors, a term that is still sometimes used for a specific type of leukaemia, 
erythroleukaemia (AML M6).  In 1938, 100 patients with refractory anaemia were reported by 
C.P. Rhoads and W. Halsey Barker, who were based in New York City (Steensma, 2011). 
Following that, in 1949, a London pathologist, J.L. Hamilton-Paterson, reported that some 
cases of refractory anaemia had a propensity to develop into leukaemia; he called this 
condition ‘pre-leukemic anaemia’. This finding was backed by several French investigators, 
who also came to similar conclusions that refractory anaemia could progress into leukaemia. In 
1953, a prominent paper by three physicians from the University of Chicago’s Medical School 
described twelve patients with ‘pre-leukemic acute human leukaemia’ in the Journal of the 
American Medical Association.  Thus, in the 1960s and 70s, what we now know as MDS was 
widely known as ‘preleukaemia’ (Steensma, 2011). Bjorkman was a pioneer in the study of 
sideroblastic anaemia in 1956; he described four cases of refractory anaemia with ‘great 
amounts of free iron in the normoblasts’ and the presence of perinuclear mitochondrial iron, 
giving the appearance of rings. By 1976, however, Dr John Bennett from Rochester, New 
York, and six other pathologists from France, the United States and Great Britain - the so-
called FAB co-operative group had noticed that most patients with preleukaemia never actually 
went on to develop leukaemia (Hellstrom-Lindberg, 2008). Then, in 1974, Van Den Berghe 
described the 5q- syndrome as the first entity within the group of refractory cytopenias with an 
interstitial deletion of 5q (Hellstrom-Lindberg, 2008). This entity is more common in females, 
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who have macrocytic anaemia, with a normal or elevated platelet count, typical megakaryocyte 
morphology and a low incidence of AML transformation. The first classification of 
leukaemias, including MDS, was made by FAB in 1976 and revised in 1982 to expand its 
applicability to MDS (Lowenthal, 2011, Bennett et al., 1985). 
Table 1-1: The French American British (FAB) Classification of MDS (1982) 
 
RA: refractory anaemia; RARS: refractory anaemia with ringed sideroblasts; RAEB: refractory anaemia with excess 
blasts; CMML: chronic myelomonocytic leukaemia; RAEB-T: refractory anaemia with excess blasts in 
transformation (Vardiman, 2012). 
In 1976, the term ‘dysmyelopoietic syndrome’ was proposed by the FAB group as an 
alternative to preleukaemia.  A few years later this was revised to ‘myelodysplastic syndrome’ 
and classified in 1982, again by the FAB group (Steensma, 2011). This classification included 
the following subtypes: refractory anaemia (RA), refractory anaemia with ring sideroblasts 
(RARS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts 
in transformation (RAEBT), and chronic myelomonocytic leukaemia (CMML). In the recent 
World Health Organization (WHO) classification, CMML and RAEB-T were removed from 
the MDS classification and RAEB was split into two groups with medullary blast counts below 
and above 10% (Gupta et al., 2010). 
During the 1990s it became evident that additional clinical variables, and in particular 
chromosome analysis, could contribute significantly to clinical outcomes and that survival and 
risk of leukemic transformation was substantially worse in patients with adverse cytogenetics 
(Hellstrom-Lindberg, 2008).  
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In 1997, Greenberg et al. introduced the International Prognostic Scoring System (IPSS), the 
database which was based on a wide range of information gathered from patient samples from 
Europe, the United States, and Japan (Greenberg et al., 1997). The first WHO classification 
was developed in 2000 and revised in 2008 (Vardiman et al., 2009). The current classification 
of MDS used by doctors globally is the WHO’s 2008 version, which was updated in 2016.   
1.3 MDS classification  
In recent years the morphological assessment of the peripheral blood and bone marrow, has 
been supplemented by the cytogenetic, molecular and immunophenotypic information. This is 
reflected in the 2008 WHO classification of MDS that uses a combination of clinical, genetic, 
immunophenotypic and morphological features from peripheral blood and bone marrow 
(Vardiman et al., 2009) and identifies six subtypes. Refractory cytopenia (RA), refractory 
anaemia with ringed sideroblasts (RARS), refractory cytopenia with multilineage dysplasia 
(RCMD), refractory anaemia with excess blasts (RAEB1 and RAEB2), myelodysplastic 
syndrome unclassifiable and myelodysplastic syndrome with isolated del5q (5q syndrome) 
(Vardiman et al., 2009). MDS with isolated del (5q) show features of ‘5q-syndrome’, 
characterised by an interstitial deletion of the long arm of chromosome 5, macrocytic anaemia, 
low probability of leukaemic transformation and normal/elevated platelet count (Vardiman et 
al., 2009). The updated 2016 WHO classification (Table 1-2) eliminates explanations of the 
cytopenic lineage (e.g., refractory anaemia) in favour of an account of the dysplastic lineages 
(MDS with single lineage dysplasia). Erythroid-predominant cases no longer bid for separate 
blast enumeration of the non-erythroid cells, a difference that will mark the reclassification of 
most acute erythroid leukaemia and erythroid/myeloid types as MDS.  
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Table 1-2: The (2016) World Health Organization (WHO) classification of MDS: Peripheral Blood 
(PB) and Bone Marrow (BM) findings and cytogenetics of MDS (Arber et al., 2016). 
 
*Cytopenias defined as: haemoglobin, 10 g/dL; platelet count, 100 x 109/L; and absolute neutrophil count, 1.8 x 
109/L. On rare occasions MDS may exhibit mild anaemia or thrombocytopenia above these levels. PB monocytes 
must be < 1 x 109/L. †If SF3B1 mutation is present. ‡1% PB blasts must be recorded on at least 2 separate 
occurrences. §Cases with >_ 15% ring sideroblasts have significant erythroid dysplasia, and are classed as MDS-







Ring Sideroblasts as % 
of marrow erythroid 
elements 
BM and PB blasts 
Cytogenetic by conventional 
karyotype analysis 
MDS with single lineage 
dysplasia (MDS-SLD) 
1 1 or 2 <    <  †
BM <5%, PB <1%, 
no Auer rods
Any, unless fulfills all criteria 
for MDS with isolated del(5q) 
MDS with multilineage 
dysplasia (MDS-MLD)
2 or 3 1-3 <    <  † 
BM <5%, PB <1%, 
no Auer rods 
Any, unless fulfills all criteria 
for MDS with isolated del(5q) 
MDS with ring 
sideroblasts (MDS-RS) 
MDS-RS with single 
lineage dysplasia (MDS-
RS-SLD) 
1 1 or 2 >_    _>  † 
BM <5%, PB <1%, 
no Auer rods 
Any, unless fulfills all criteria 




2 or 3 1 - 3 >_    _>  † 
BM <5%, PB <1%, 
no Auer rods 
Any, unless fulfills all criteria 
for MDS with isolated del(5q) 
MDS with isolated 
del(5q) 
1 - 3 1 - 2 None or any 
BM <5%, PB <1%, 
no Auer rods 
del(5q) alone or with 1 
additional abnormality except 
-7 or del (7q) 
MDS with excess 
blasts (MDS-EB) 
MDS-EB-1         None or any 
BM 5%-9% or PB 
 %-4%, no Auer 
rods 
Any 
MDS-EB-2         None or any 
BM 10%-19% or PB 
       




With 1% blood blasts 1-3 1-3 None or any 
BM <5%, PB =1%‡ 
, no Auer rods 
Any




None or any BM <5%, PB <1%, 
no Auer rods
Any
Based on defining 
cytogenetic abnormality
0 1-3
<15% BM <5%, PB <1%, 
no Auer rods
MDS-defining abnormality 
Refractory cytopenia of 
childhood 
1-3 1-3 None BM <5%, PB <2%, Any
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SF3B1 mutation, if present, enables a diagnosis of MDS with ring sideroblasts when even 
fewer than 5% ring sideroblasts are displayed. A diagnosis of MDS with isolated del (5q) may 
possibly be made if one additional cytogenetic abnormality is present, with the exclusion of 
monosomy 7 or del (7q). For the time being, the detection of other somatic gene mutations are 
excluded as a diagnostic criterion for MDS, because of the challenges posed by age related 
Clonal Haematopoiesis of Indeterminate Potential (CHIP) (Arber et al., 2016), Idiopathic 
Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenia of Undetermined 
Significance (CCUS). CHIP is characterised by the acquisition of somatic mutations that drive 
clonal expansion in the absence of cytopenias and dysplastic haematopoiesis. The most 
frequently mutated genes associated with CHIP are DNMT3A, TET2, and ASXL1 (Abdel-
Wahab and Levine, 2013). Most individuals who acquire clonal haematopoiesis in later ages 
never progress to developing MDS (Steensma et al., 2015). The absence of cytopenias and 
dysplastic haematopoiesis differentiates CHIP from MDS. ICUS patients on the other hand are 
characterised by persistent blood cytopenias of unknown cause, and display unremarkable 
marrow morphology that lack a known MDS-associated somatic mutation or karyotypic 
abnormality (Valent et al., 2012). Some individuals with ICUS have been shown to have 
progressed and developed MDS or AML (Hanson, 2009). CCUS patients are characterised by 
unexplained cytopenias and a clonal mutation, who however do not meet WHO defined criteria 
for MDS or other heamatologic neoplasm (Malcovati and Cazzola, 2015, Steensma et al., 
2015). Prognostic systems, such as the IPSS (Greenberg et al., 1997) (Table 1-3) and its 
revision (IPSS-R) (Table 1-4) have been developed and validated for MDS patients (van 
Spronsen et al., 2017, Della Porta et al., 2015, Greenberg et al., 2012). Three prognostic 
indicators are used by the IPSS to predict the course of the patient’s disease. There are three 
variables; bone marrow blasts, karyotype and cytopenia which are utilised to predict survival 
and AML evolution (Greenberg et al., 1997, Lim et al., 2007, Gupta et al., 2010).  
The patient’s IPSS risk category is determined by adding up the IPSS scores within the three 
disease factors, which matches the patient to one of the following four IPSS risk categories: 
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low, intermediate-1, intermediate-2 or high. At times the low and intermediate-1 categories are 
combined into a lower risk group, while the intermediate-2 and high categories are together 
denoted as higher risk group. 
The modified IPSS, known as the IPSS-R, covers the same disease factors as the IPSS but in 
greater detail particularly in relation to cytogenetic abnormalities (Table 1-4). The IPSS-R was 
established using data sets from an initial group of 7,012 patients with primary MDS; this 
system enabled MDS patients to be classified into five groups (from very low to very high) 
showing varied estimated overall survival and progression to AML (Greenberg et al., 2012). In 
addition to cytogenetics, values for haemoglobin and platelet counts are given different score 
depending on whether the level is <8 or ≥ 10 in the case of former and <50 or ≥ 100 in the case 
of later. A patient’s IPSS-R risk category is established by tallying the individual IPSS-R 
scores for the defined values within the five disease subgroups. Five IPSS-R risk classes are 
defined as very low, low, intermediate, high and very high. 
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Table 1-3: International prognostic scoring system (IPSS) classification of MDS 
 
* Bone marrow blasts of 20-30% may imply MDS (according to the French-American-British (FAB) classification) 
or AML (according to WHO). ** Cytopenia defined as neutrophils <1.8x109 /L, platelets <100x109 /L, haemoglobin 
<10g/dl. *** Cytogenetics (Karyotype): Good = normal, -Y alone, del (5q) alone or del (20q) alone; Poor = 
complex (>_3 abnormalities) or chromosome 7 abnormalities (Greenberg et al., 1997, Gupta et al., 2010). 
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Table 1-4: Revised International prognostic scoring system (IPSS-R) classification of MDS 
 
 




1.4 Implication of Cytogenetic abnormalities in MDS 
Cytogenetic abnormalities provide important information with respect to the diagnosis, 
prognosis and appropriate treatment options in patients with MDS. Several chromosomal 
deletions are associated with the development of MDS and its associated complications. MDS 
is characterized by frequent cytogenetic aberrations such as deletions on the long arms on 
chromosomes 5, 7 and 20, as well as more complex karyotypes such as trisomy 8 and other 
chromosomal lesions such as del Y, 20q-, 3q26 (Gerstung et al., 2015).  
Chromosome 5q deletion (5q- syndrome) was first reported over four decades ago (Van den 
Berghe et al., 1974) and is a distinct subtype of MDS characterised by the presence of an 
isolated interstitial deletion of chromosome 5q and <5% blasts in the bone marrow (Boultwood 
et al., 1994, Giagounidis et al., 2004). 5q- syndrome is also regarded as a disease of 
haematopoietic stem cell (Gordillo et al., 2008). In patients with MDS, the 5q- syndrome is the 
most common cytogenetic abnormality, with an incidence of between 10-15% of MDS patients 
carrying this mutation either as the sole karyotypic abnormality or in combination with other 
chromosomal abnormalities (Sole et al., 2000, Heim and Mitelman, 1986).   
Chromosome 7 and 7q deletions are a distinct subtype of MDS characterised by the deletion of 
part of the long arm of chromosome 7 (7q), total loss of chromosome 7 (monosomy 7), or 
translocations involving chromosome 7, and can be present either as a single anomaly or in 
combination with other anomalies such as -5/del(5q) and trisomy 8 (Cordoba et al., 2012). 
Either in isolation or as a part of a complex karyotype, about 10% of patients harbour 
abnormality of chromosome 7 and this incidence increases to 50% in tMDS patients with 
alkylating agent’s treatment history (Christiansen et al., 2004). In terms of prognosis, MDS 
patients with 7q deletion have been shown to be associated with fewer blasts in bone marrow, 
and significantly higher survival superiority (i.e. better prognosis) than in those with isolated 
monosomy 7 (Cordoba et al., 2012). Moreover, other evidence shows that the outcome is better 
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when -7 or del (7q) occurs in MDS patients with a simple karyotype, compared with those with 
a complex karyotype (Woo et al., 2009). 
Trisomy 8 is a fatal condition characterised by the presence of three copies of chromosome 8 
in every cell of an individual's body (Gilbert-Barness E, 1991). The condition is present as a 
sole abnormality in approximately 8% of the patients and is the only recurrent observed 
chromosomal amplification. It is observed as an intermediate cytogenetic abnormality. 
Compared with patients with normal karyotype, individuals with Trisomy 8 have a life span 
less than half the median expected survival. The clone size influences the prognostic factor in 
MDS, and in Trisomy 8 patients with a clone size (aberrant metaphases) of 100% have been 
shown to have a shorter survival (Mallo et al., 2011). 
Chromosomal lesions such as del Y, 20q-, 3q26 have been reported in MDS (Nardi and 
Hasserjian, 2016). Both –Y and 20q are regarded as being in the same favourable cytogenetic 
risk group as patients with a normal karyotype (Yun et al., 2011). There is no correlation 
between the loss of chromosome Y with disease pathogenesis while interstitial loss of 20q 
appears to be pathogenic not only in MDS but also myeloproliferative disorders and AML 
(Wiktor et al., 2000).  
The most frequent cytogenetic abnormalities along with their frequency of incidence and 
prognostic impact are detailed in (Table 1-5) below: 
Table 1-5: Common cytogenetic abnormalities and their frequency of incidence in MDS and their 
impact on prognosis (Haase et al., 2007, Bejar, 2014). 
Chromosomal abnormalities Frequency (%) Prognosis 
Trisomy 8  5 to 8 Good 
Trisomy 21  2.7 Good 
del 5q 15 Good  
del 20q 2 to 5 Good  
del Y  0.8 Good  
-7/del 7q  5 to 10 Intermediate to poor 
del 17p 10 Poor 




1.5 MDS Therapeutic Implications 
Owing to the heterogeneous nature of MDS, treatments are tailored to the predicted prognosis 
for each patient; hence the accurate prediction of the prognosis is essential component in the 
overall patient care. MDS are mostly diagnosed in the elderly (median age range 65 to 70 
years). The International Prognostic Scoring System (IPSS-R) is a widely used tool to assess 
the risk of MDS transformation to leukaemia and to guide treatment decisions by physicians. 
Both karyotypic abnormalities and patient’s clinical features are considered in determining the 
risk of an individual. IPSS-R takes into account the patient's age and associated co-morbidities, 
patient's expectations and personal goals. In younger age patients with high risk of disease, 
stem cell transplantation and chemotherapy are usually considered. MDS patients need both 
supportive care/therapy as well as curative treatment options. Care of MDS patients involve 
both supportive care and curative treatment options. 
Haemoglobin levels in MDS patients are generally maintained between 8 and 10 g/dL. Patient 
with a low or intermediate-1 risk and having a haemoglobin level greater than 10 g/dL and 
platelet counts of 50,000/μL to 100,000/μL do not usually need blood transfusion; these 
patients are often classified ‘watch and wait’ with regular observation in monitoring them (Ria 
et al., 2009). Supportive therapy for severe MDS patients may include blood transfusions to 
replenish red cells and platelets based on clinical evaluation of anaemia-related symptoms and 
any associated secondary infections (Ria et al., 2009), reducing cytopenia, and improving the 
quality of life through the administration of immunosuppressive drugs, iron chelation therapy, 
treatment of infectious or heamorrhagic complications, and psychological support to patients 
and relatives (Sanchez, 2011). The potential danger of iron overload in the elderly due to 
transfusion may prompt the requirement of iron chelating agents, with the administration of 
oral deferasirox (Exjade
®
: 20 to 40 mg/kg per day) in transfusion-dependent MDS patients 
seen to induce a significant reduction of the mean serum ferritin after 12 months of therapy 
(List et al., 2012). Erythropoiesis-stimulating agents such as recombinant human 
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erythropoietins used as a monotherapy in doses ranging from 30,000 to 60,000 units/week 
induced erythroid responses in about 15% of MDS patients (Hellstrom-Lindberg, 1995). 
Furthermore, the pancytopenia observed in most MDS patients warrants the prophylactic use 
of granulocyte colony-stimulating factor in patients with severe neutropenia and recurrent 
infections (Ria et al., 2009). Severe thrombocytopenia with chronic bleeding is common in 
MDS and is associated with shortened survival and impaired quality of life (Ria et al., 2009). 
Platelet transfusions may therefore be necessary to provide short-term relief for bleeding 
tendencies. The Food and Drug Administration (FDA) approved drug AMG 531 is effective 
for the treatment of immune thrombocytopenia MDS patients (Tiu and Sekeres, 2008). DNA 
methyltransferase (DNMT) are involved in the post-mitotic modification of DNA methylation, 
while in cancers and conditions such as MDS the mechanisms controlling methylation can 
become dysregulated.  
Demethylating agents have been shown to be the standard therapy for patients with higher-risk 
MDS and the currently known agents to improve the natural history of MDS (Garcia-Manero, 
2008). Demethylating agents are a group of chemotherapeutic agents that are able to induce 
transient DNA hypomethylation. The FDA has in recent times approved three hypomethylating 
agents for the treatment of MDS, these are 5- azacitidine, 5-aza-2′-deoxycitidine (decitabine), 
and the immunomodulatory drug Lenalidomide (Diesch et al., 2016, Silverman et al., 2002). 
These agents have significant activity in patients with higher risk MDS and are widely used in 
the USA and other European countries. In 5q- type of MDS, lenalidomide is often used as the 
first treatment choice followed by, treatment with azacitidine or decitabine option lenalidomide 
fails. Contrary, treatment with azacitidine or decitabine is often the first choice for patients 
with the non 5q- type MDS. 
Lenalidomide is an immunomodulatory drug that is a synthetic compound derived by 
modifying the chemical structure of thalidomide; it is a 4-amino-glutamyl analogue of 
thalidomide but lacks the neurologic side effects of sedation and neuropathy associated with 
thalidomide. Lenalidomide has different mechanisms in different haematological disorders. 
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Although the exact mechanism of action of lenalidomide on del 5q- MDS patients is unknown 
it is widely known to modulate different components of the immune system by altering 
cytokine production, regulating T-cell co-stimulation and augmenting the NK cell cytotoxicity 
(Kotla et al., 2009).  
In high-risk MDS (intermediate-2 and high IPSS), it is important to modify the natural history 
of the disease by eliminating the malignant clone to prevent the early progression to AML and 
the associated short median overall survival in these groups. Bone marrow transplantation is 
usually considered the only curative option for these patients, especially younger patients with 
MDS (recommended treatment for nearly all children), and is usually performed as soon as 
possible, although it requires that a matched donor to found (Sierra et al., 2002, Cutler et al., 
2004). Such procedures have associated morbidity and mortality, including the possible 
mutations of genes in allogenic bone marrow transplant patient. For example, a recent study 
found at least 1 mutation in 1196 of 1514 patients (79%) who had undergone bone marrow 
transplantation, with a median of 2 driver mutations per patient (range, 0 to 15) (Lindsley et 
al., 2017). The authors found that mutations such as TP53 and DNMT3A that are associated 
with higher-risk MDS according to the IPSS, were more prevalent in patients with MDS who 
had undergone transplantation than those who did not receive any transplant, whereas 
mutations that are associated with lower-risk MDS, such as SF3B1, were less prevalent. 
The TP53 mutation was significantly associated with shorter overall survival compared with 






II. Immune system in MDS  
 
1.1 The clinical evidence of Autoimmunity in MDS 
The pathophysiology of MDS remains poorly defined; this is attributable to the heterogeneric 
nature of the disease. Genetic mutations, and clonal karyotypic abnormalities are a hallmark of 
this group of diseases. In addition to these, several lines of evidence suggest that defective 
innate and adaptive immune responses are a common feature of MDS including altered 
cytokine/chemokine profile which is also implicated in MDS pathogenesis. Several studies 
have reported strong association between autoimmunity and MDS, with up to 10% of MDS 
patients reported to have a concomitant autoimmune disorders (Mufti et al., 1985, Mufti and 
Galton, 1986, Hamblin, 1996). That include such as vasculitis, arthritis, peripheral neuropathy, 
pulmonary infiltrates, inflammatory bowel disease, connective tissue disorders, 
glomerulonephritis, thyroid abnormalities, sweets syndrome and autoimmune cytopenias 
(Castro et al., 1991, Billstrom et al., 1995, Saif et al., 2002). Clinical evidence to support the 
association of autoimmunity with MDS include the presence of both organ and non-organ 
specific autoantibodies in over a fifth of MDS patients, the presence of both monoclonal 
gammopathies and polyclonal hypergammaglobulinaemia in just above a tenth of MDS 
patients and hypogammaglobulinaemia in half of all MDS cases (Mufti et al., 1986).  
1.2 Innate Immune cells in MDS 
1.2.1 Natural Killer Cells (NK cells) and MDS 
As part of the innate arm of immune system natural killer (NK) cells are important part of the 
first line of defence against both intracellular pathogens and tumour cells (Grossenbacher et 
al., 2017, Stabile et al., 2017). NK cells regulate tumour initiation via their ability to recognize 
and kill malignant cells, and synchronise with the adaptive immune response by 
releasing cytokines and chemokines (Stabile et al., 2017). A few studies have explored the 
contribution of NK cells in MDS, with some reports of normal levels but impaired function of 
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NK cells (Epling-Burnette et al., 2007a, Kiladjian et al., 2006, Chamuleau et al., 2009). These 
impaired function of NK cells in high-risk MDS may facilitate disease progression. In one of 
the above studies, the authors showed that reduced NK cells function in MDS patients was 
significantly associated with higher International Prognostic Score, abnormal karyotype, the 
presence of excess blasts, and age-adjusted bone marrow hypercellularity. MDS patients with a 
display of the activating receptor NKp30, and NKG2D down-regulation closely correlated with 
impaired NK function (Epling-Burnette et al., 2007a). 
 NK cells have been found to have high expressions of Leukocyte Immunoglobulin-like 
receptor 1 (LIR1) (Jain et al., 2017), (an inhibitory molecule) which induces leukaemia-killing 
impairment (Godal et al., 2010). NK cells are functionally impaired in high-risk MDS 
(Carlsten et al., 2010, Jain et al., 2017). However, in low and intermediate risk MDS, NK cell 
expression of granzyme B is high with non-major histocompatibility complex (MHC) directed 
killing of autologous haematopoietic precursor cells being increased (Chamuleau et al., 2009) 
(Table 1-6). 
Table 1-6: The role of immune responses in MDS 
 
The role of cellular innate and adaptive immune responses in MDS depending on whether it is high-risk or low-risk. 
Increase in number and decrease in frequency (Aggarwal et al., 2011).  
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1.2.2  iNKT cells and MDS 
Although the exact contribution of invariant (i) NKT-cells remains debatable, they are reported 
to contribute primarily to innate and adaptive immune response modulation via dendritic cell 
(DC) activation or elimination (Aggarwal et al., 2011). Activated iNKT-cells secrete both 
inflammatory (e.g. IFN-γ, TNF-α) and anti- inflammatory (e.g. IL-4, IL-13) cytokines, thus 
providing a potential for preventing autoimmunity as well as promoting host anti-cancer 
immunity to cancer (Aggarwal et al., 2011, Molling et al., 2008).  Although three different 
studies have shown decreased levels of iNKT-cells in MDS, they were limited by the lack of 
control age-matched group. Later studies demonstrated that levels of iNKT cell decreased with 
age (Fujii et al., 2003, Zeng et al., 2002). However, Chan et. al., showed that there was no 
difference in the levels of iNKT cells between age-matched MDS patients and the healthy 
control group (Chan et al., 2010) (Table 1-6). 
1.2.3 Dendritic cells (DC) and MDS 
Dendritic cells (DCs) are professional antigen presenting cells that act as regulators of 
immunity. DCs are classified as either myeloid and plasmacytoid DC and can be distinguished 
based on their morphology, surface phenotype and specificity of response to antigenic signals. 
Both myeloid and plasmacytoid DC stimulate a primary T-cell response to antigen (Knight et 
al., 2002). Their role in MDS has gained major attention. It has been shown that the absolute 
numbers of the two DC subsets in the peripheral blood of MDS patients are lower than in 
healthy controls, and that both populations were derived from the malignant clone (Ma et al., 
2004). Monocyte-derived DC have been shown to be clonally involved in MDS patients with 
refractory anaemia, and refractory anaemia with excess blasts with karyotype abnormalities 
(Matteo Rigolin et al., 1999). This observation contrast that observed in CMML in which the 
yield and immunophenotypic maturation of monocyte-derived DC are less dramatically altered 
(Vuckovic et al., 1999) and in AML where myeloid or lymphoid derived DC numbers can be 
unaltered, decreased or increased  (Mohty et al., 2001) (Table 1-6).  
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1.2.4 Gamma delta (γδ) T-cells and MDS 
γδ T-cells play an important role in the rapid response against both tumour and non-tumour 
cells and are an important component of lymphoid stress-surveillance response (Hayday, 2009, 
Band et al., 1990, Kunzmann et al., 2000, Kunzmann and Wilhelm, 2005)). γδ T-cells bearing 
the Vγ9Vδ2 rearrangement constitute just about a tenth of circulating peripheral blood T-cells, 
a proportion which even further lowered in MDS patients (Kiladjian et al., 2008). The results 
were most profound in MDS patients with associated autoimmune disorders. In the above, the 
authors reported that in a subset of MDS patients the γδ T-cells failed to expand in response to 
bromohalohydrin pyrophosphate and demonstrated limited proliferative potential in response 
to IL-2, however, the cytolytic function was preserved in those where expansion was observed 
(Kiladjian et al., 2008). All these results demonstrate the complexity of the immune 
dysregulation in MDS.  
1.2.5 Inflammasome and MDS 
Recent studies have shown that the NLR family pyrin domain-containing 3 (NLRP3) 
inflammasome plays a major role in MDS by directing clonal expansion and pyroptotic cell 
death. Independent of genotype, MDS hematopoietic stem and progenitor cells overexpressed 
inflammasome proteins and manifest activated NLRP3 complexes that direct the activation of 
caspase-1, IL-1b and IL-18 generation, and pyroptosis (Basiorka et al., 2016). 
1.2.6 Monocytes and MDS 
Monocytes are professional phagocytic cells of the innate immune system that migrate from 
the circulation and extravasate through the endothelium, where they differentiate into 
macrophages. Monocytes generated from T-helper cell activation contribute to immune 
dysregulation of MDS (Meers et al., 2007). A number of studies have hypothesised that the 
CD40-CD40 ligand could affect immune-mediated bone marrow (BM) failure in MDS. CD40-
stimulation of monocytes in MDS results in high TNF-α secretion in MDS. Furthermore, bone 
marrow mononuclear cells co-cultured with CD40 blocking antibody increased colony-
forming units (Meers et al., 2007). In MDS patients an increased monocyte count, but impaired 
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ability to induce macrophages, resulting in reduced number of macrophages compared with 
normal control group has been observed (Han et al., 2016). This reduced macrophage count 
usually result in increased levels of iNOS secreted by macrophages in MDS (Han et al., 2016). 
1.2.7 Macrophages and MDS 
Macrophages are innate immune cells derived from monocytes. They are distributed 
throughout the body tissues, and function to ingest and degrade abnormal cells, debris, and 
foreign material and orchestrate inflammatory processes. Macrophages engage in the clearance 
of debris from apoptotic bone marrow haematopoietic cells (Dogusan et al., 2004, Lambert et 
al., 2016). DAMPs and PAMPs are strong ligands for PRRs (Lambert et al., 2016). The toll-
like receptor 4 (TLR4), amongst the PRRs, is over-expressed by macrophages in MDS as well 
as by stem cells and stromal cells (Lambert et al., 2016, Wei et al., 2013) (Table 1-6).  
A high frequency of bone marrow (BM) macrophages is usually observed in MDS (Kitagawa 
et al., 1993, Sadahira et al., 1999). An increase in the frequency of macrophages in high-risk 
MDS patients compared to low-risk patients mediates angiogenesis via the production of basic 
fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and increased 
stimulation of pro-inflammatory cytokines, thus possibly explaining the increased cellular 
death in the BM of LR-MDS patients (Wetzler et al., 1995). Furthermore, elevated levels of 
soluble angiogenic factors (VGEF) in high-risk MDS patients are reported to contribute to 
immunosuppression. This suggests that inhibition of activated macrophage function at initial 
stages of MDS development may improve BM homeostasis in low-risk MDS cases and 
thereby reduce inflammation associated apoptosis (Table 1-6) (Aggarwal et al., 2011).  
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1.3 The role of the adaptive immune response in MDS: T-cell biology of MDS 
1.3.1 Concept of T-cell oligoclonality in MDS and response to immunosuppressive 
therapy 
Oligoclonal is defined as a small group of proteins that migrate close together during 
electrophoresis producing closely placed bands on the electrophoretogram. In MDS patients 
increased CD8
+
 cytotoxic T lymphocytes (CTLs) displaying an effector phenotype are a 
common feature (Melenhorst et al., 2002, Epling-Burnette et al., 2007b, Kook et al., 2001). A 
lower CD8
+ 
CTLs count has been observed in high-risk MDS compared to low-risk MDS 
patients (Epling-Burnette et al., 2007b, Fozza et al., 2009, Sloand et al., 2011, Chamuleau et 
al., 2009). Although MDS is defined by cytopenias, dysplastic morphology of blood and 
marrow cells, and clonal haematopoiesis, most individuals who acquire clonal haematopoiesis 
during aging do not progress to developing MDS (Steensma et al., 2015). Clonal 
haematopoiesis must be exhibited by a somatic mutation with a variant allele frequency of at 
least 2% (Steensma et al., 2015). MDS and other haematological disorders such as aplastic 
anaemia display oligoclonal T-cells (Wlodarski et al., 2006, Risitano et al., 2002). Oligoclonal 
T-cells are not only a feature of MDS, they can also be seen in other haematological disorders 
such as aplastic anaemia, T-cell large granulocytic leukaemia and paroxysmal nocturnal 
haemoglobinuria (PNH) (Wlodarski et al., 2006, Risitano et al., 2002, O'Keefe et al., 2004). In 
MDS patients, while no correlation has been seen between clonality and disease severity, a 
correlation between a positive response to immunosuppressive therapy and a loss of clonal T-
cells was observed in patients treated with immunosuppressive (Wlodarski et al., 2006). In 
addition, clonally restricted haematopoiesis is associated with increased risk of subsequent 
diagnosis of myeloid or lymphoid neoplasia (Steensma et al., 2015).  
Several hypotheses have been suggested as the underlying mechanism of autoimmunity in 
MDS. Some propose that cytomegalovirus (CMV) infection in which prevalence increases 
with age, may be the cause of the expansion of CD8
+ 
CTLs, while an alternative hypothesis 
proposes that effector T-cells may be triggered as a result of increased apoptotic cytokines and 
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aberrant expression of oncogenes or fusion genes in haematopoietic stem cells (Epperson et al., 
2001). In addition to immune surveillance, immune responses can promote tumour growth. A 
number of studies have proposed dysregulation of the immune system in the intricate MDS 
pathogenesis. Immune dysregulation could potentially promote progression of MDS from 
lower/early risk to higher/advance risk MDS. Lower-risk MDS is often characterized by 
autoimmune disease-like features (such as increased T-helper cell type 17 (Th17); increased 
levels of pro-apoptotic cytokines; low regulatory T-cells (Treg) number; dysfunctional B-cells) 
while higher risk MDS is marked with low apoptosis, immune invasion, increased Treg and 
dysfunctional natural killer (NK) cells (see Table 1-6). Reports such as that of Pellagatti et al. 
show that MDS accounts for aberrant immune responses (Pellagatti et al., 2010). This 
perturbed response results in disease symptoms such as cytopenia often affecting both normal 
and dysplastic cells (Pellagatti et al., 2010), making treatment quite challenging. 
1.4 T-cells dysregulation in MDS 
1.4.1 CD8
+
 cytotoxic T lymphocytes (CTLs) 
MDS is characterized by high levels of effector phenotypic CD8
+
 cytotoxic T lymphocytes 
(CTLs) (Melenhorst et al., 2002, Epling-Burnette et al., 2007b). MDS and other 
haematological disorders such as aplastic anaemia display oligoclonal T-cells (Wlodarski et 
al., 2006, Risitano et al., 2002). Several studies have reported a positive correlation between 
loss of clonal T-cells in MDS patients and positive response to immunosuppressive therapy 
(Wlodarski et al., 2006), with some groups reporting high levels of oligoclonal T-cells in MDS 
in comparison to controls (Kochenderfer et al., 2002). Similarly, a low number of CD8
+ 
CTLs 
has been observed in high-risk MDS in contrast to low-risk MDS (Table 1-6) (Epling-Burnette 
et al., 2007b, Fozza et al., 2009, Sloand et al., 2011, Chamuleau et al., 2009). 
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1.4.2 Regulatory T-cells (Tregs) 













. Key functions of Tregs include immune tolerance and modulation of 
immune response during immune surveillance (Wang et al., 2018). These functions are 
performed via secreting immunosuppressive cytokines such as IL10 and TGF-Beta (Aggarwal 
et al., 2011). Defective immune activation and a decreased immune surveillance against the 
tumor cells are characteristic of impaired Tregs (Selma D’Silva, 2019). Moreover, reduced 
numbers of functional Tregs result in autoimmunity. 
Although the exact role of Tregs in MDS progression is not very clear, various reports have 
linked variation in number of Tregs with disease progression, risk of transformation to AML 
and overall survival in MDS patients (Mailloux and Young, 2010, Lambert et al., 2016). Tregs 
involvement in MDS was first shown by Kordasti et al. (Kordasti et al., 2007), in which the 
authors demonstrated an association between increased CD4
+
 Tregs and disease progression. 
Various studies have shown an association between low number of Tregs in bone marrow and 
increased CD8
+
 T-cells and the recruitment of Th17 proinflammatory cells (Alfinito et al., 
2010, Kordasti et al., 2009). The number of Tregs however differs based on the stage of the 
disease. For example, in low-risk MDS, lower numbers of Tregs or impaired Tregs have been 
reported in association with T-cell cytotoxicity leading to increased apoptosis, whereas, higher 
number of Tregs are seen in high-risk MDS patients and are associated with impaired 
antineoplastic immunity and immune suppression (Kotsianidis et al., 2009, Zou et al., 2009).  
A study that investigated the effect of 5-azacytidine on Tregs functionality in 
intermediate/high-risk MDS patients reported that following treatment, lower numbers and 
Tregs with lower suppressive function were observed in those patients (Costantini et al., 2013). 
Others have also reported an inverse relationship between levels of Tregs and the degree of 
dyserythropoiesis (Alfinito et al., 2010), and an inverse ratio between Treg and 
CD8
+
 frequencies in MDS patients (Hamdi et al., 2009). Low-risk MDS patients have higher 
number of Th17 cells which is inversely correlated with Tregs numbers. This results in an 
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increased Th17/Tregs ratio in such patients (Kordasti et al., 2009). Furthermore, an increased 
number of Th22 (IL22 producing T-cells) in high-risk MDS patients has been reported (Shao 
et al., 2012) and is correlated with release of pro-inflammatory cytokines leading to increased 
apoptosis. 
1.4.3  Th17 cells 
Th-17 cells are also referred to as CD4
+
 IL-17 producing T-cells (Dong, 2008). Low risk MDS 
is associated with a pro-inflammatory milieu where an increase in the levels of IL-17, IL-12, 
RANTES and IFN-γ were observed (Kordasti et al., 2009). In contrast, high amounts of the 
anti-inflammatory cytokine IL-10 and its soluble IL-2R were noted in high-risk stages 
(Kordasti et al., 2009).  A high ratio of Th-17 cells to Tregs was demonstrated in low risk 
MDS and the inverse is true for the high-risk form, showcasing an inverse correlation between 













III. The complement systems 
 
1.1 Introduction 
The complement system is one of the oldest and most important components of innate 
immunity. It is often regarded as the first line of immunological defence and is a component of 
the innate immune system (Bajic et al., 2015), which does not change over a person's lifetime 
(Janeway et al., 2001). The complement system is deemed an effector arm of innate immunity, 
steering the identification and destruction of microbes in body fluids (Bennett et al., 2017). 
Since its discovery in 1896 by Bordet, complement was for a long time associated with innate 
immunity until increasing evidence of the interplay between innate and adaptive immunity 
shed light on the contribution of complement to both innate and adaptive immune responses 
(Lambris et al., 2008, Zipfel et al., 2007, Garcia et al., 2016). Complement system comprises 
more than 50 circulating and membrane-bound proteins (Bajic et al., 2015). Most soluble 
components of the complement system are synthesized by the liver, although the occurrence of 
extrahepatic complement biosynthesis is also seen in other cell types (fibroblasts, T and B 
cells, adipocytes and endothelial cells), wherein the complement components are transported 
as inactive pro-proteins (Bennett et al., 2017, Morgan and Gasque, 1997).  
1.2 Complement Components, Receptors and Regulators 
1.2.1 CD46 
CD46 (also known as membrane cofactor protein, MCP), a complement receptor on T-cells, 
plays a key part in modulating T-cell responses. CD46 is a transmembrane complement 
regulatory protein and serves as an inhibitor of complement activation on host cells and 
protects host tissue against unwanted complement deposition by functioning as a cofactor in 
the factor I- mediated degradation of C3b/C4b (Riley-Vargas et al., 2004). In humans, CD46 is 
expressed on all nucleated cells in four major isoforms (BC1, BC2, C1 and C2) that arise 
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through alternative splicing of a single gene (Figure 1-1). The N-terminus of CD46 consists of 
four so-called ‘short consensus repeats’ (SCRs) that contain the complement control function. 
This is followed by a heavily O-glycosylated region (differentially spliced B and C), a region 
of unknown function, a transmembrane anchor and one of two possible cytoplasmic domains, 
CYT-1 or CYT-2. Besides its role as a complement regulator, CD46 is also involved in the 
regulation of T-cell responses (Riley-Vargas et al., 2004). Activation of human primary CD4
+
 
T-cells in the company of CD46 cross-linking antibodies induces the development of a definite 
immunomodulatory T-cell population characterized by high IL-10/granzyme B production 
(Kemper and Atkinson, 2007). This response depends on signalling events mediated by 
cytoplasmic tails of CD46. In addition, CD46 is a receptor several important human pathogens 
including bacteria and viruses (Cattaneo, 2004) (Figure 1-1). CD46 is involved in the down-
modulation of adaptive Th1 immune responses by the regulation of IFN-γ and IL-10 
production in the T helper cells (Cardone et al., 2011). Deficiency of CD46 is seen as a 
predisposing factor for many diseases causing complement-mediated ‘self-attack’ (Nesargikar 
et al., 2012). 
 
Figure 1-1: CD46, Structure and functions. CD46 is a complement regulatory protein 
In humans, CD46 is expressed as four major isoforms (BC1, BC2, C1 and C2) on all nucleated cells. All four 
isoforms express short consensus repeats (SCRs) 1-4 on their N-terminus, followed by an alternatively spliced B or 
C region, transmembrane region and one of two possible tails, Cyt-1 or Cyt-2.   
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1.2.2 C3a and C5a and their receptors (C3aR, C5aR1, C5aR2) 
The anaphylatoxins C3a and C5a are released when the convertases cleave C3 and C5 
respectively and exert their biological functions after binding to seven-transmembrane domain 
(7TM) receptors in the membranes of host cells. Two of these receptors, C3aR and C5aR1 
(CD88), are G protein-coupled receptors (GPCR), the third, C5aR2 (formerly known as C5L2), 
is structurally like C5aR1 but does not couple to heterotrimeric G proteins (Li et al., 2013).  
C5aR2 was first sought as a decoy receptor (does not undergo ligand-induced internalization), 
limiting the availability of the C5a and C5 adesArg ligands to C5aR1. C5aR2 may reduce the 
cellular responses to pro-inflammatory molecules and thus actively regulate inflammatory 
processes (Rittirsch et al., 2008). 
Anaphylatoxins play an important role in chronic inflammatory diseases such as rheumatoid 
arthritis, inflammatory bowel disease, and in asthma and allergy (Linton and Morgan, 1999, 
Woodruff et al., 2003, Hawlisch et al., 2004). C3a causes an anti-inflammatory response 
dependent on the cell type activated through C3a–C3aR signalling and the phase of 
inflammation (Coulthard and Woodruff, 2015). Anaphylatoxins are involved in tissue 
regeneration and development (Mastellos et al., 2001, Strey et al., 2003, Hillebrandt et al., 
2005); in the liver, C3a induces STAT3 activation and an increase in IL-6 production (He et 
al., 2009); in the eye, C3a signalling activates STAT3 and promotes retinal regeneration 
(Haynes et al., 2013). C3a is further associated with neural stem cell migration and 
regeneration (Shinjyo et al., 2009), and C3aR has been implicated in alloreactivity (Asgari et 
al., 2013). 
1.3 Complement and Adaptive Immunity (Intracellular Complement in T-Cells) 
Activation of opposing functional phenotypes of CD4
+
 T-cells is dependent on local 
complement (Figures 1-2 A and B) (Le Friec et al., 2013). The C3a and C5a that are locally 
produced bind to their receptors, functioning as autocrine and paracrine stimulators of T-cells 
and APCs (Soruri et al., 2003). Signalling through these G-protein-coupled receptors (GPCRs) 
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in T-cells leads to the activation of phosphoinositide-3-kinase-ã and induction of 
phosphorylation of phosphokinase B (AKT), upregulating the antiapoptotic protein (Bcl-2) and 
downregulating the proapoptotic molecule (Fas) (Le Friec et al., 2013, Soruri et al., 2003, 
Strainic et al., 2008). The expression of complement receptors C3aR and C5aR have been 
shown in peripheral, murine, natural regulatory T-cells (nTregs); signalling through these 
receptors inhibits Treg function (Le Friec et al., 2013). Mechanisms such as C3a/C5a-induced 
phosphorylation of AKT phosphorylate, the transcription factor Foxo1, result in lowered 
expression of Treg and Foxp3 (Le Friec et al., 2013). The co-stimulatory molecule signalling 
by CD28/CD80/CD86 and CD154/CD40 together minimize cell surface-expressed DAF, thus 
hampering complement activation, consequently resulting in the above changes (Cravedi and 
Heeger, 2015). DAF-deficient APC-induced T-cell expansion is seen to increase with 
diminished T-cell apoptosis (Lalli et al., 2008).  
The proliferation of T-cells is enhanced and T-cell apoptosis is diminished by complement-
dependent mechanisms (Lalli et al., 2008). T-cell homeostasis also requires C3aR/C5aR 
signalling; deficiency in both receptors leads to spontaneous accelerated T-cell death both in 
vitro and in vivo (Cravedi et al., 2013). C3 or C3 fragments are not secreted in individuals with 
serum C3 deficiency. Th1 cell responses are further severely diminished; however, sufficient 
intracellular C3a can be generated, mediating T-cell survival. This supports the hypothesis that 
C3aR is multi-functional at particular cellular locations (Liszewski et al., 2013). It has been 
observed that C3-deficient patients (in early childhood), CD46- deficient patients (throughout 
life) have greatly reduced Th1 cell- mediated responses (Th2 cell responses are normal) as well 
as a recurrence of infections, suggesting a difference in the complement-mediated signalling 
pathways contributing to the induction of Th1 cells in mice and humans (Ghannam et al., 2008, 
Le Friec et al., 2012). The results and findings largely portray, with regards to T-cell biology, a 
functional role of complement activation (Dunkelberger and Song, 2010). At the organism 
level, adequate evidence supports a relationship between complement activation and 
augmented T-cell immune response (Dunkelberger and Song, 2010).  
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Figure 1-2: A and B: Opposing functional phenotypes of CD4
+
 T cells dependent on activation 
in the presence or absence of local complement. 
(A) The production of anaphylatoxins locally and induction of effector responses in Th1 or Th17 
cells results from DC activation via the Toll-like receptor (TLR) engagement. Stimulatory 
molecules, major histocompatibility complex (MHC) class II, CD80 and CD86, as well as C3aR 
and C5aR, are upregulated by activated DCs, which also secrete components C3, C5, fB (factor B) 
and fD (Factor D) and downregulate CD55 (1). A functional C3 convertase is formed by C3, fB and 
fD under this circumstance, leading to local generation of C3a and C5a (2). C3a and C5a ‘loop 
back’ onto the DC by engaging with their respective receptors C3aR and C5aR, the expression of 
costimulators are sustained and the secretion of IL-6, IL-12 or IL-23 are induced (2). For the T cell, 
signals mediated by CD28, a costimulatory molecule, induce C3aR and C5aR expression, and 
lowered C3, C5, fB and fD secretion. The engagement of DC-derived C3a and C5a with their 
respective receptors on the T cells, induce IL-12R expression, activate phosphatidylinositol-3-OH 
kinase-ã (PI(3)K), inhibit PKA via cAMP generation inhibition, which consequently enables 
phosphorylation of Akt at Thr308 and Ser473 (p- Akt(Thr308,Ser473)) and ensues activation of 
mTORC1 and S6 (phosphorylation of S6 (p- S6)) (3) which are necessary for IFN-γ and IL-2 
production. The balance is then tipped between Th1 and Th17 responses by DC-derived IL-6, IL-12 
or IL-23, acting as cytokine prompts (Le Friec et al., 2013). 
 
(B) No activation of receptors for pathogen-associated molecular pattern (PAMP) on DCs 
results in Foxp3+ iTreg cell induction and no local generation of anaphylatoxins. Minimal 
expression of CD80, CD86, C3aR and C5aR and low secretion of C3, C5 and fB and fD are 
seen when DCs are activated under tolerogenic conditions (1). There is the initiation of 
TGF-β production with a positive feedback loop, and suppression of proinflammatory 
cytokine secretion. The lack of DC-secreted anaphylatoxins and hence lack of signalling via 
the receptors in T cells enables PKA activation, consequently inhibiting configuration of the 
mTORC1 complex, preventing production of IFN-γ and IL-2, releasing the ‘constraint’ on 
the production of TGF-β and inducing suppressive Foxp3+ iTreg cells (2). IL-6 secretion is 
suppressed by TGF-β production, resulting in phosphorylation of p-Smad2 (the TGF-βR 
signal transducer Smad2) and expression of the transcription factor Foxp3 and of the 
receptor C5L2 (2). Local C5a are hunted by the receptor C5L2, ensuring sustained absence 
of its receptor C5aR from engaging. Under these conditions, both DC and T cell-produced 
TGF-β reciprocally sustain suppressive or tolerogenic phenotypes in both cells (3) (Le Friec 




The main aim of this PhD project was to investigate the potential role of intracellular 
complement system in polarisation and function of CD4
+
 T-cells in MDS. 
Project objectives 
The main objective of this thesis was to elucidate the role of intracellular complement 
components (C3a and C5a), regulators (CD46) and their receptors (C3aR, C5aR1 and C5L2) in 
the CD4
+
 T-cells polirization and switching towards Tregs phenotype, which is one of the main 
factors in the progression of HR-MDS patients towards AML. Specifically, the research sub 
objectives were: 
1.  To investigate whether there are differences between MDS and healthy donors in terms 
of intracellular and surface complement receptors (C3aR, C5aR1 and C5L2) and 
complement component (C3a and C5a) and if so, any differential expression between 
low and high-risk disease. Also, any potential differences between HDs, LR and HR-
MDS in response to complement pathway activator (mainly CD46). 
2. The main signalling pathways for polarising CD4+ T-cells which including mTOR, and 
TGF-β signalling and associated proteins were investigated following stimulation with 
anti-CD46 in both HDs and MDS patients.  
3. To identify additional pathways which may differentially expressed in T-cells from 
MDS patients compared to HDs, Tconv and Tregs were stimulated with anti-CD46 
(with or without complement components) followed by RNA extraction for gene 






T-cells play a pivotal role in the pathogenesis of MDS. It has been shown that Tregs are 
increased in high risk MDS and correlate with poorer prognosis whereas pro-inflammatory T 
helper 1 (Th1) and T helper 17 (Th17) T-cells are the main feature in the low risk disease. 
Considering the importance of intracellular complement machinery in the polarisation of CD4
+
 
T-cells, I hypothesised that the malfunctioning of this machinery is crucial in Treg expansion 





Chapter 2. Material and Methods 
 
The materials and methods used in this study are described below. 
2.1 Sample preparation and culture 
2.1.1 Patient sample and Ethical approval 
Blood samples were obtained from 22 healthy donors and 44 MDS patients (out of which 22 
had low-risk and 22 had high-risk MDS) with a median age of 67 years (range 35‐86 years). 
Patients were risk classified according to the WHO and IPSS criteria. The WHO subtypes and 
IPSS risk groups of patients are summarized in Tables 1-2 and 1-3 (Chapter 1). Written 
informed consent was obtained from all patients, including healthy donors, in accordance with 
the Declaration of Helsinki, approved by the King’s College London Hospital Research Ethics 
Committee, and licensed by the Human Tissue Authority HTA (License no. 11023). All donors 
gave full informed consent prior to sample collection. The data did not include any 
identification information from the patients and was handled only by the members of the 










2.1.2 Peripheral blood mononuclear cell (PBMC) isolation  
PBMCs were isolated using a Ficoll-based gradient cell separation technique as follows: 15 ml 
of citrate anti-coagulated blood was taken from each donor and was carefully added onto 15 ml 
of Ficoll-Paque medium (GE Healthcare Life Science, Piscataway, New Jersey, USA) in a 50 
ml Falcon tube (Greiner Bio-one, Chicago, USA), and then centrifuged at 450 g for 20 minutes 
at room temperature, with the brake off. Three layers were observed, with the layer of PBMCs 
(thick /buffy coat) lying between a layer of plasma and a layer of Ficoll-Paque medium. After 
aspiration using a sterile Pasteur pipette, the PBMCs were transferred into 50 ml Falcon tubes, 
washed twice with Hanks’ Balanced Salt Solution (HBSS) with phenol red (Sigma-Aldrich, 
London, UK) in a final volume of 50 ml and centrifuged at 400 g for 5 minutes (brake on). 
After each wash, the supernatant was discarded and the final cell pellet was re-suspended in 8 
ml of R10 medium comprising RPMI 1640 (Sigma-Aldrich, London, UK) supplemented with 
10% fetal bovine serum (FBS) (50 ml) (Sigma-Aldrich, London, UK), and 5 ml of 100% (1x 
penicillin/streptomycin at a working concentration of 100,000 I.U.), penicillin/100,000 g/ml 
streptomycin per litre (Sigma-Aldrich, London, UK)).  
Cells were counted using a haemocytometer and the density of cells was adjusted by the 
addition of medium to achieve a plating density of 1 million cells/ml cultured in 6-well tissue 
culture-treated plates (VWR international ltd, UK) or tissue culture flasks (VWR international 
ltd, UK). The cells were grown in an incubator at 37°C in humidified air containing 5% CO2. 
2.2 Peripheral blood mononuclear cell (PBMC) activation  
The PBMCs were activated for 24 h in 48-well culture plates (2.0 - 5.0 x 10
5 
cells/well) left 
uncoated or coated with mAbs to CD3 (2.0 g/ml), CD3 (2.0 g/ml) + CD28 (3.0 g/ml) or CD3 
(2.0 g/ml) + CD46 (2.0 g/ml). The cells were grown in an incubator at 37°C
 
in humidified air 




 T-cell isolation and activation 
The PBMCs were separated using a ficoll-based gradient cell separation technique, as 
discussed in (2.1.2 section), and the CD4
+
 T-cells were isolated using the MACS Human CD4
+
 
T-Cell Isolation Kit (Miltenyi Biotec, order no. 130-091-301, USA) following the 
manufacturer’s instructions. CD4+ T-cells were activated in 48-well culture plates (2.0-5.0x105 
cells/well) left uncoated or coated with mABs to CD3 (2.0 µg/ml) alone, Anti-CD3 (2.0 
µg/mL) + anti-CD28 (3.0 µg/mL) or anti-CD46 (2.0 µg/mL) antibodies were used to stimulate 
cells. Cells were untreated or treated with a combination of C3a/C5a (50 nM each). The cells 
were incubated for 24 hr at 37°C in a humidified atmosphere containing 5% CO2.  After 
culturing for 24 hr, 48-well culture plates were agitated gently to remove loosely adherent cells 









 (Treg.) cells isolation and activation 
The PBMCs were separated using a ficoll-based gradient cell separation technique, as 













 Treg Cell Isolation Kit (Miltenyi Biotec, order no. 130-091-301, USA) 
following the manufacturer’s instructions. Purity of the isolated lymphocyte fractions was 
>95%. CD4
+
 T-cells were activated in 48-well culture plates (2.0-5.0x10
5
 cells/well) left 
uncoated or coated with mABs to CD3 (2.0 µg/ml) alone, Anti-CD3 (2.0 µg/mL) + anti-CD28 
(3.0 µg/mL) or Anti-CD3 (2.0 µg/mL) + anti-CD46 (2.0 µg/mL) antibodies. Then cells were 
untreated or treated with a combination of C3a/C5a (50 nM each). The cells were incubated for 
24 hr at 37°C in a humidified atmosphere containing 5% CO2.  After culturing for 24 hr, 48-
well culture plates were agitated gently to remove loosely adherent cells before analysis. Cells 
were centrifuged at 300 g for 10 minutes and the supernatant were discarded. The cell pellet 
was re-suspended in 1ml Triazol and the vials were kept in -80 before using over the night.  
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2.3 Cryopreservation of cells 
A ‘Mr. Frosty’ freezer container was pre-cooled in the fridge at 4°C and 1.8 ml sterile 
cryovials were labelled with the LSL number (sample identifier), name, date and cell number. 
After harvesting, the cells were centrifuged at 300 g for 10 minutes. After disposal of the 
supernatant, the cell pellet was re-suspended in a freezing mix, the serum-free and 
commercially prepared Synth-a-Freeze (Life Technologies, Order number A1254201), using 1 
ml of the freezing mix per 5-10 x 10
6
 PBMCs. The re-suspended cell pellet was aliquoted, 1 ml 
per vial, placed in a ‘Mr Frosty’ container (pre-cooled at 4°C) and frozen at -80°C overnight 
before being transferred to liquid nitrogen for long-term storage in vapour phase.  
2.4 Thawing of cryopreserved cells 
Cell cryovials from liquid nitrogen were thawed in a 37°C water bath for the minimum period 
necessary, then gently added drop-by-drop into 10 ml of pre-warmed R10 and centrifuged at 
300 g for 10 minutes. The cells were washed twice with pre-warmed R10. After disposal of the 
supernatant, the cell pellet was re-suspended in 3 ml R10 (the volume of the media being 
dependent on the pellet size and cell number) and cells were counted and seeded in 6 well 
tissue culture-treated plates or tissue culture flasks. The cells were grown in an incubator at 
37°C in humidified air containing 5% CO2.  
2.5 Cell counting  
A mixture of 10μl of cell suspension and 10μl trypan exclusion was transferred into the 
counting chamber and all cells in the central large square of the haemocytometer were counted. 
The total number of cells was calculated: Cell count (25 sq grid) x dilution factor x 10
4 
x 
volume of the cell suspension. To assess the viability of cells, trypan blue dye was used in the 
ratio of 1:1 and the total calculated cell number was multiplied by 2.  
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2.6 Cell staining 
2.6.1 Gating and Compensation  
Before running the samples, compensation adjustment was carried to prevent cross laser 
channels and the overlap of the colours, using BD CompBeads (BD Biosciences). The proper 
laser voltages were verified by running the setup beads (BD Biosciences), using FACSDiva 
software (BD Biosciences). These procedures ensured the consistency of laser readings 
throughout the entire project. The stained samples were run on the FACS machine after initial 
checks and compensation and started by 1 minute of acquisition at low speed to identify the 
targeted population followed by data recording of interested events. FACSDiva software (BD 
Biosciences) and Flow Jo software (Tristar, USA) were used to produce FACS plots for the 
thesis.  
2.6.2 Surface staining 
The PBMCs were harvested from the culture wells. Cell viability was monitored using Trypan 
blue and examination by light/optical microscopy. 2.0 x 10
5 
to 1.0 x 10
6 
cells were used per 
test for surface staining. Harvested cells were then transferred to pre-labelled FACS tubes 
(VWR, Chicago, USA). Alternatively, suspension cells were collected directly into FACS 
tubes for staining. In each case, cells were centrifuged at 300 g for 10 minutes. 500μl of 
supernatant was collected for later measurement of cytokine content. After removing the traces 
of supernatant, cells were re-suspended in 1 ml of phosphate buffered saline (PBS) only 
(without proteins). 1 μl of the live/dead efluor 780 dye (eBioscience Cat. No. 650865) was 
added to the cell pellet. Cells were then incubated for 30 minutes in the dark at room 
temperature (RT) and then washed twice by adding 1 ml of cold PBS and centrifuged at 300 g 
for 10 minutes. Specific antibodies (anti-CD4, anti-CD3, anti-CD25, anti-CD45RA and anti-
CD127, anti-C3aR and anti-C5aR1) or (anti-CD4, anti-CD3, anti-CD25, anti-CD45RA and 
anti-CD127, anti-CD46 and anti-C5aR2 (C5L2)) antibody (4μl per 1 x 106 cells) were then 
added and topped up with cold PBS to final volume of 100 μl. Capped tubes were mixed by 
pulse vortexing followed by incubation in the dark at RT for 30 minutes. Following a further 
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wash in 2ml of cold PBS, cells were centrifuged at 300 g for 10 minutes. The supernatant was 
carefully aspirated from the tubes. After washing, the pellets were loosened by pulse vortexing 
the capped tubes. 1ml of freshly prepared eBioscience Fixation/Permeabilisation solution was 
added. The solution was added slowly, and the capped tubes were pulse vortexed and 
incubated for 30-60 minutes in the dark at 4°C before adding 2ml of 1x eBioscience 
Permeabilisation buffer directly to the tubes (total volume 3 ml) and cells were centrifuged at 
300 g for 10 minutes. The supernatant was aspirated carefully, and the pellets were re-
suspended by vortexing, washed again with 2 ml of 1x eBioscience Permeabilization buffer 
and centrifuged at 300 g for 10 minutes. 4μl of FOXP3 antibody was added and incubated for 
30 minutes in the dark at 4°C. The cells were washed again with 2 ml of 1x eBioscience 
Permeabilization buffer and centrifuged at 300 g for 10 minutes. The supernatant was aspirated 
carefully, and the pellets were re-suspended by pulse vortexing. 200 μl of FACS buffer (PBS 
with 1% FCS) was added and the cells re-suspended to obtain a single cell suspension. Bound 
antibodies were then quantified by flow cytometry using a FACS Canto II or Fortessa Flow 
Cytometer.  
2.6.3 Intracellular staining (IC) 
Intracellular staining (eBioscience, Cat. No. 00-5123) was used for the detection and analysis 
of intracellular complement system proteins following the manufacturer’s instructions. The 
steps of intracellular staining are similar to that of surface staining except where noted in the 
protocol; anti-C3aR and anti-C5aR1, anti-CD46 and anti-C5aR2 (C5L2) antibodies (4μl of 





The reagents which were used in this study are described below: 
Table 2-2: The two antibody panels used for the compensation and surface/intracellular 
antibodies cocktail for CD4
+
 T-cells. 
First Panel Second Panel 
C5aR1 PE (4μl/106) CD46 PE (4μl/10
6) 
C3aR APC (4μl/106) C5L2 (C5aR2) APC (4μl/106) 
CD3 V500 (4μl/106) CD3 V500 (4μl/106) 
CD4 efluor 450 (4μl/106) CD4 efluor 450 (4μl/106) 
L/D efluor780 (4μl/106) L/D efluor 780 (4μl/106) 
CD25 BV650 (4μl/106) CD25 BV650 (4μl/106) 
CD127 PerCp/Cy5.5 (4μl/106) CD127 PerCp/Cy5.5  (4μl/106) 
CD45RA Alexa Fluor 700 (4μl/106) CD45RA Alexa Fluor 700 (4μl/106) 
FOXP3 FITC (4μl/106) FOXP3 FITC (4μl/106) 
 
Fluorochrome antibodies were used for the fluorescence-activated cell (FACS) analysis as 
follows (Table 2-3): 
Table 2-3: The antibodies and reagents used for the compensation and surface/intracellular 
antibodies cocktail for CD4
+
 T-cells. 
Antibodies and reagents Manufacturer 
Anti-human PE CD46  Biolegend, CA, Cat. No. 352402 
Anti-human PE C5aR1  Biolegend, CA, Cat. No. 344304 
Anti-human APC C5aR2 (C5L2) antibody Biolegend, CA, Cat. No. 342406 
Anti-human APC C3aR  Biolegend, CA, Cat. No. 345806 
Anti-human PerCp/Cy5.5 CD127  eBioscience, CA, Ref. No. 45-1278-42 
Anti-human BV650 CD25 BioLegend, CA, Cat. No. 302634 
Anti-human FITC FOXP3  eBioscience, CA, Ref. No. 11-4776- 42 
Anti-human Alexa Fluor 700 CD45RA  BioLegend, CA, Cat. No. 304120 
Human CD3-VGTM  MACS, mitenyi Biotechnology, UK, order No. 130- 098-164 
Anti-human efluor®450 CD4  eBioscience, CA, Ref. No. 48-0049-42 
Recombinant human complement component C3a R&D Systems, Cat. No. 3677-C3 
Recombinant human complement component C5a R&D Systems, Cat. No. 2037-C5/CF 
Live/Dead efluor780 dye  eBioscience Cat. No. 650865 
UltraComp eBeads  eBioscience, CA, Ref. No. 01-2222-42 
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Table 2-4: Tissue culture reagents and equipment: 
Reagents and Materials Manufacturer 
Roswell Park Memorial Institute medium (RPMI-1640) Sigma Aldrich 
Fetal Bovine Serum (FBS) 
Penicillin/Streptomycin/Ciprofloxicin 
Sigma-Aldrich 
L-Glutamine-Penicillin – Streptomycin solution Sigma-Aldrich 
Phosphate Buffered Saline (PBS) PPA 
15ml & 50ml Falcon tubes 
Vented tissue culture flasks 
5ml, 10ml & 20ml Pipettes 
6,12, 24, 48 and 96 well plates 
VWR international ltd 
1.5 ml microcentrifuge ‘Eppendorf tubes’ Starlabs 
Trypan Blue 0.4% , 0.85% NaCl Lonza 
Dimethyl sulfoxide (DMSO) (freezing cells) Sigma 
Neubauer Improved Haemocytometer VWR international 
 
Table 2-5: Purified Complements 
Purified Complements Clone Manufacturer 
Anti-human Purified CD46 TRA-2-10 Biolegend, CA, Cat. No. 352404 
Anti-human Purified CD3 ------------ eBioscience, CA, Ref. No. 16-0037-85 
 
2.8 Flow cytometry analysis 
Flow cytometry was used to analyse the activation of CD4
+
 T-cells in the PBMCs and was also 
used to measure the level of surface and intracellular expression with stained markers. Cells 
were identified by the placement of gates using forward versus side scatter dot plots that had 
earlier been optimized to detect T-effector cells and T-regulatory cells as appropriate. Changes 
in fluorescence intensity resulting from the binding of fluorescently labelled antibodies to cells 
were expressed as mean fluorescence. A minimum of 10,000 events was collected per sample. 
Data were analysed using the FACS Canto II or the Fortessa Flow Cytometer. 
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2.9 Western blotting 
Samples and controls were separated by SDS-PAGE under reducing conditions and transferred 
onto membrane. 







 T-cells were collected in 1.5 ml eppendorf tubes (Physiocare 
eppendorf AG, Hamburg, Germany) and centrifuged at 300 xg (Bifuge Pico-heraeus, Slough, 
UK) for 3 minutes and the supernatants were discarded. The tubes were centrifuged again at 
300 xg for 30 seconds to remove the traces of media were removed. The dry pellets were 
flicked to disaggregate the cells and re-suspended in 12.5-25 µl 1X Nupage LDS sample buffer 
(Invitrogen, cat# NP0007, USA) + 10% Dithiothreitol (DTT) (100mM) (Applichem GmbH, 
Ottoweg, Germany) depending on the cell count.  
Following vigorous mixing, the samples were boiled (Techne
®
, Dri-block DB.3, UK) at 70° C 
- 90° C for 8 min prior to separation by SDS-PAGE (Nupage 4-12% Bis-Tris Gel 1.0 mm x 12 
well, Invitrogen-novex by life technologies
TM
, USA) to denature the proteins completely. Each 
tube was centrifuged at 13,000-x g for 5 minutes and the supernatant was utilized for SDS-
PAGE Nu-polyacrylamide gel (4-12 % Bis- Tris Gel) separation. 
2.9.2 Western blot analysis  
Following protein extraction by SDS-PAGE, western blotting was carried out on the samples. 
Nu-polyacrylamide gel (4-12 % Bis-Tris Gel) was placed in the electrophoresis tank 
(Invitrogen-Novex Mini-Cell, by Life Technologies, USA), which was filled with 1x MES 
SDS running buffer (NuPage
®
 by Life Technologies). Protein samples were loaded (6-10 μl) 
along with 6 μl Precision Plus Protein™ Dual Xtra Prestained Protein Standards ladder (2-250 
KD) (Cat# 1610377, Bio-RAD, Canada) to determine the molecular weight (MW) of the 
proteins. Electrophoresis was carried out at a constant voltage (200V) at run time 45 minutes 
(MES Buffer) until the dye reached the bottom of the gel. Next, the NuPage Bis-Tris gel was 
placed under a nitrocellulose-coated nylon membrane (Amersham, Hybond ECL, 
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Buckinghamshire, UK) and then sandwiched between blot filter paper (Bio-RAD, USA) and 
nylon pads soaked in NuPage transfer buffer. Proteins separated in the gel were transferred 
onto the nitrocellulose membrane by cold electrophoresis at 30 V constant for 120 min. Actin 
was used as a loading control (anti-beta actin (1:1000), Abcam Ab8226, 1 mg/ml). After the 
transfer, the nitrocellulose membrane was blocked for 1 hour with 5 % (w/v) dried skimmed 
milk (Marvel, UK) diluted in 1% PBS- 0.1 % (v/v) Tween 20
®
 (Fisher scientific BP337-500, 
USA) and rinsed with 1% PBS- 0.1 % (v/v) Tween20
®
. As primary antibodies, mouse 
monoclonal anti-C5a/C5a des Arg antibody (2952, ab11878) or mouse monoclonal anti-
C3a/C3a des Arg antibody (K13/16, ab36385) were used in the (1:500) dilution indicated 
previously in 1% (w/v) dried skimmed milk, 1%PBS-0.1% (v/v) Tween 20
®
, and incubated in 
the rotator overnight at 4°C. Membranes were subsequently washed three times in 1% PBS-
0.1% (v/v) Tween20
®
 for 15 minutes. This was followed by incubation for 1 h with the 
(1:1000) goat anti-mouse IgG-HRP (Abcam ab205719) secondary antibody in 1% (w/v) dried 
skimmed milk and 1% PBS 0.1% (v/v) Tween 20
®
 at RT. Membranes were washed three times 
in 1% PBS- 0.1 % (v/v) Tween20
®
 for 10 minutes. Bound antibodies were detected by 
incubation with ECL Western Blot substrate (Thermo-scientific, USA) for 3-5 minutes. The 
membranes were then sealed in Saran wrap and exposed to hyper film ECL developed using 
film developer system (Konica Minolta SRX101A, UK).  
Table 2-6: The buffers and reagents used for the western blot 
Reagents Preparation 
1X PBS 10 tablets were dissolved in 1 litre of dH20 
1X sample buffer 
 
20 % (v/v) NuPAGE LDS Samples Buffer (4 x), 10 % (v/v) β- 
mercaptoethanol were made up in dH20 and stored at - 20°C. 
 
NuPage Transfer buffer 
 
50 ml 20X NuPage transfer buffer, 20  % Methanol (v/v), dH20 upto 1 litre 
 
1x MES SDS Running buffer 
Buffer made by 1: 20 dilution of 20X Running buffer in dH20.  
 
The 1X Solution composed of 50 mM MES, 50mM Tris Base, 0.1 % SDS 












Table 2-7: The antibodies used for the western blot 
Primary Dilution Manufacturer 
Mouse monoclonal anti-C3a/C3a des Arg antibody 1:500 Abcam ab36385 
Mouse monoclonal anti-C5a/C5a des Arg antibody 1: 500 Abcamab11878 
β-Actin 1: 1000 Abcam ab8226 
Secondary Dilution Manufacturer 
Goat anti-mouse IgG-HRP 1:1000 Abcam ab205719  
 
2.10 Total protein extraction (BCA Protein Assay) and quantification by colorimetric 
methods 
The total protein was extracted by bicinchoninic acid (BCA) and quantified using nano-drop. 
The Pierce BCA Protein Kit (Thermo Scientific Cat. 23225 sufficient for 500 tests) was used 
for total protein extraction following the manufacturer's instructions. The procedure involves 
the lysing of cells for extraction of the total protein using RIPA buffer and the BCA Protein kit 
for its quantification by colorimetric methods using a Nano-Drop spectrophotometer and 
measured as the absorbance at 540-562 nm. The BCA Protein kit is provided with a standard 
bovine serum albumin (BSA) solution of a known protein concentration. The kit allows the 
preparation of a series of dilutions to generate a standard curve of absorbance against protein 
concentration. Finally, the concentration of each unknown sample was determined based on 






Table 2-8: Standard curve (concentration of protein in µg/mL versus absorbance) 
 
2.10.1 Protein extraction Reagents 
1. Culture and thawing media (sterile): RPMI with 10% FCS and 1% Penicillin/Streptomycin. 
5 ml P/S stock aliquots (100x, 10,000 units/ml penicillin, 10mg/ml streptomycin) were kept at  
-20°C. Once defrosted, they can be stored at 4°C for up to one month. 
2.  Phosphate buffered saline (PBS), with Calcium (II) and Magnesium (II). Bottles were kept 
sterile by working with only the aliquots taken inside the hood. 
3. RIPA lysing buffer kit (Santa Cruz SC-24948). Aliquots containing 1.5mL were stored at     
-20°C. Aliquots were thawed as needed. There are other providers and the preparation of the 
buffer might be different. The kit contained PMFS, sodium ortho-vanadate in water, a protease 
inhibitor and 1x lysis buffer.  
 65 
4. BCA Reagent A (1000 mL): containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid (BCA) and sodium tartrate in 0.1 M sodium hydroxide. 
5. BCA Reagent B (25 mL): containing 4% cupric sulphate.  
6. Working reagent (WR) diluent preparation: Total WR volume: 2400 µL (Stds) + 40 µL (9 
Stds + Number of unknown samples). For example, for 4 unknown samples, the following was 
prepared: 2400 + 40 x (9 + 4) = 2920 µL (5 mL prepared). WR is 50 parts of BCA Reagent A 
plus 1 part of BCA Reagent B. Therefore, for 5 mL: 5 mL BCA A plus 0.1 mL BCA B (mixed 
until it became green in colour). 
2.10.2 Cell lysis procedure 
After 24 hr of incubation, the CD4
+





 cells were used per test for the total protein extraction. Harvested cells were then 
transferred to pre-labelled Eppendorf tubes (for cell lysis) (Fisher Scientific, Product code 
15128344).  
In each case, cells were centrifuged at 300 g for 10 minutes. 500μl of supernatant was 
collected for later measurement of cytokine content. After removing the traces of supernatant, 
cells were washed twice with ice cold phosphate buffered saline (PBS), then re-suspended in 
250 µL of PBS (ice-cold) and pelleted in the micro-centrifuge at 3000g for 2 minutes, after 
which the supernatant was carefully removed. The complete RIPA buffer was prepared in the 
following way:  
1 mL of complete RIPA buffer prepared for lysing up to 10
7
 cells by mixing 10 µL of PMFS, 
10 µL of sodium ortho-vanadate in water, 20 µL of protease inhibitor and 960 µL of 1x lysis 
buffer. Cells were re-suspended in lysing buffer (35 µL per tube), pulse vortexed to mix up and 
then cells were incubated by maintaining constant agitation for 30 minutes at 4°C (using ice 
box). The cells were pelleted in the micro-centrifuge for 20 minutes at 16000 g and 4°C to give 
the supernatant containing the total protein. 
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2.10.3 Preparing standard dilutions 
The Pierce BCA Protein Kit was used to prepare the bovine serum albumin (BSA) diluted 
standards. One ampule contained 2 mg/mL BSA in PBS (top standard). For preparation of the 
standards, the instructions provided by the kit were followed: Micro-plate procedure (working 
range 20-2000 µg/mL) (See Table 2-9). 5 µL of each standard dilution or unknown sample 
was pipetted into wells in a 96-well plate. 40 µL of the working reagent (WR) was added to all 
wells and mixed by pipetting up and down several times or putting the plate on the shaker for 
30 seconds. The plate was covered, incubated at 37°C for 30 minutes and left to cool down at 
room temperature (RT). The protein quantification was measured at 562nm absorbance using a 
Nano Drop spectrophotometer 2000/2000c.  A standard curve (concentration of protein in 
µg/mL versus absorbance) was generated in an Excel spreadsheet and the protein 
concentrations in the samples were extrapolated from it (Table 2-9).  
Table 2-9: Preparation of Diluted Albumin (BSA) Standards 
 
2.11 Luminex immunoassay (Total TGF-β Protein expressions of phosphorylated 
mTOR, PI3K/Akt, ERK, Smad2, Smad3, Smad4 and TGFRβII employing Luminex® 
technology) 
The MILLIPLEX MAP Human TGF-β Signaling Magnetic Bead Panel 6-plex- Cell Signaling 
Multiplex Kit 96-well Plate Assay (Cat. # 48-614MAG) was used to detect the signalling 
changes in phosphorylated mTOR, PI3K/Akt, ERK, Smad2 (Ser465/Ser467) and Smad3 
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(Ser423/Ser425), as well as total protein levels of TGFRβII and Smad4 in cell lysates using the 
Luminex® system following the manufacturer's instructions. 25 ug of sample was used in each 
well and the immunoassay was carried out according to the published protocol for this kit. 
Although the TGFβ pathway regulates a wide range of processes, the pathway is fairly simple. 
TGFβ dimers bind to a TGFβ Type II Receptor, which recruits and phosphorylates a TGFβ 
Type I Receptor. The Type I Receptor then recruits and phosphorylates SMAD2/3, which then 
binds to SMAD4 and forms a complex that enters the cell nucleus, where it acts as a 
transcription factor for various genes. The TGFβ Receptor activates the SMAD-dependent 
canonical pathway, as well as SMAD-independent non-canonical pathways, such as mTOR, 
PI3K/Akt, ERK, JNK, and p38. The data was acquired on a Luminex 200TM (Luminex 
Corporation, Austin, TX, USA). The Luminex 200™ instrument with xMAP® technology 
system and xPONENT® acquisition software were employed to capture component detection. 
Milliplex® Analyst 5.1 software was adopted to integrate data acquisition and analysis. 
2.11.1 Luminex immunoassay protocol: 
Day 1 
A.  Preparation of reagents 
 1x capture beads 
The 20x stock magnetic beads were sonicated for 15 seconds, vortexed for 30 seconds and 
then the beads were diluted to 1x by combining 150 µL (TGF-beta 6-plex) + 150 µL 
(mTOR MAPmate) beads with 2.7 mL of assay buffer 2 in mixing bottles. The 1x capture 
beads were further vortexed for 15 seconds.  
 Lyophilized cell lysate 
There were three vials provided in the kit: unstimulated Hela lysate negative control, 
HepG2 stimulated with TGFb 60 min lysate, and MCF7 stimulated with IGF-1 for 10 
minutes. All vials were reconstituted by adding 100 µL ultra-pure water (final 
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concentration of protein 2 mg/L) and kept for 5 minutes at RT. 150 µL of AB2 were added 
to each bottle, vortexed and stored on ice till use.  
B. Protocols 
Samples were centrifuged at 10000 g for 5 minutes to bring any particles to the bottom. 
Wetting the plate was done by adding 50 µL AB2 and then shaking for 10 minutes. It was 
covered and sealed with autoclave tape to avoid splashes. The buffer was decanted in the 
sink, and dried well on paper towels. To each well the following were added: 25 µL 1x 
capture beads + 25 µL AB2 to the blank wells or control reconstituted lysates in duplicate 
or unknown samples (only one well per sample) and incubated overnight (16-20 hours) at 
2-8°C on a plate shaker (600-800 rpm) protected from light. 
Day 2 
A. Preparation of reagents 
 Preparation of Biotin-Labeled Detection Antibody 
The 20x detection antibody stock was vortexed for 10 seconds, and centrifuged briefly 
after vortexing for complete recovery of contents. The detection antibody was diluted to 1x 
by combining 150 µL (TGF-beta 6-plex) + 150µL (mTOR MAPmate) biotin with 2.7 mL 
of assay buffer 2 (AB2) in mixing bottles. The 1x biotin was further vortexed for 15 
seconds.  
 Preparation of Streptavidin-PE Detection Antibody 
This was provided as a 20x stock solution. The Streptavidin-Phycoerythrin 1:25 (SAPE) 
was vortexed for 10 seconds. SAPE was diluted by combining 120 µL of Streptavidin-
Phycoerythrin with 2.88 mL of Cell Signalling Assay Buffer 2 using one of the mixing 
vials provided. The1X biotinylated detection antibody and SAPE were transferred with a 




A handheld magnetic separation block was attached to the plate after removing it from the 
shaker, allowing 60 seconds for beads to settle and then decanting the samples and 
controls. After removing the plate from the magnetic separation block, it was washed with 
100 mL Assay Buffer per well and repeated for a total of two washes. 25 µL/well of 1x 
Milliplex
®
 Map Detection Antibody was added, the plate was sealed, covered with a lid 
and incubated with agitation on a plate shaker for 1 hour at room temperature (20- 25°C). 
The Magnetic Separation Block was attached, and after 60 seconds the Detection Antibody 
was decanted. 25 µL of 1x Milliplex
®
 Map Streptavidin-Phycoerythrin (SAPE) was added, 
then the plate was sealed, covered with a lid and incubated with agitation on a plate shaker 
for 15 minutes at room temperature (20-25°C). The SAPE was not removed. 25 µL of 
Amplification Buffer was added to each well, the plate was sealed, covered with lid and 
incubated with agitation on a plate shaker for 15 minutes at room temperature (20- 25°C). 
The Magnetic Separation Block was attached, and after 60 seconds the 
SAPE/Amplification buffer was decanted. The beads were suspended in 150 µL of 
Milliplex
®




2.12 Cytokine assay 
To determine serum cytokine levels, cytokines were assayed in supernatants using the 
ProcartaPlex Human Cytokine and Chemokine 34-plex Antibody Bead Kit (ThermoFisher 
Scientific, Waltham, MA USA, Cat no: EPX340-12167-901) according to the 
manufacturer’s instructions, and data were gathered by a Luminex 200TM (Luminex 
Corporation, Austin, TX, USA). Many cytokines, chemokines and related proteins were 
quantified with ProcartaPlex Human Cytokine and Chemokine 34-plex supplemented kit 
using a Luminex MagPix system and Luminex xPonent Software. The culture medium 
samples were assayed undiluted. Milliplex Analyst software (VigeneTech) was used for 
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the multiplex assay data extraction. The level of each cytokine was calculated from a 
standard curve derived from known controls. Supernatant samples were taken at 24 h time 
points before and after stimulation. Cytokines, chemokines and related proteins were 
identified as in the (Table 2-10): 
Table 2-10: List of cytokines, chemokines and related proteins quantified 
 
Cytokines, chemokines and related proteins 
Eotaxin 
Granulocyte macrophage colony stimulating factor (GM-CSF) 
Melanoma growth stimulatory activity alpha (GRO-α) 
Interferon alpha 1 (FNA1) 
Interferon gamma (FNG) 
Interferon-gamma inducible protein-10 (IP-10) 
Monocyte chemoattractant protein (MCP-1) 
Macrophage inflammatory protein 1-alpha (MIP-1α) 
Macrophage inflammatory protein 1-beta (MIP-1β) 
Regulated on activation, normal T-cell expressed and secreted (RANTES) 
Stromal cell-derived factor 1 alpha (SDF-1α) 
Tumour necrosis factor-alpha (TNF-α) 
Tumour necrosis factor-beta (TNF-β) 
Interleukin (IL)-10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-1a, IL-1β, IL-1RA, IL-2, IL-21, IL-22, 
IL-23, IL-27, IL-31, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9 
 
2.12.1 Cytokine Assay Protocol 
A. Preparing test samples 
Test samples were thawed just before use and spun down at 10000 g for 2 minutes to bring any 
impurities to the bottom of the tube. The appropriate volumes of samples (cell culture 
supernatants: 60 µL) were dispensed into a 96-well V-bottom plate, which was then covered 
(sealed with tape) and frozen down at -20
o
C overnight for next day analysis. 
B. Preparing buffers  
 Wash buffer (1x): 200 mL dilute 20 mL of the stock (10x) bottle was prepared and 
added to 180 mL of deionized water in a glass bottle. This was allowed to warm up to 
room temperature before use. The wash buffer (1x) can be stored at 2-8 
o
C for up to 
six months. 
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 Universal Assay Buffer (1x) (UAB): This is provided at the right dilution in some 
kits, if not, then the instructions for that particular kit needs to be followed. The UAB 
(1x) can be stored at 2-8
o
C for up to 30 days. 
 C. Thawing samples 
The plate with samples was taken from the freezer and placed on ice to thaw. 
D. Preparing standards  
Each of the different antigen standard vials was centrifuged to mix A and B at 2000 x g for 10 
seconds to collect the contents at the bottom of the bottles. 250 µL of UAB was dispensed in 
Standard Mix A bottle and the vials were gently vortexed for 30 seconds and incubated on ice 
for 5-10 minutes to give the Diluted Standard Mix A. 250 µL of the Diluted Standard Mix A 
was transferred into the Standard Mix B bottle and vortexed gently for 30 seconds, followed by 
incubation on ice for 5-10 minutes to give the Diluted Standard Mix B (DSM B). The 
remaining standards were prepared from serial dilution 1:4 with UAB of the DSM B (top 
standard) (Table 2-11), making sure to change the tips every time. Once prepared, the standard 
tubes were stored on ice until needed. 2 x 8 small Eppendorf tubes in a rack (standards are 
done in replicate) were prepared and 150 µL was added to tubes 2 to 7. Tube 1 was the top 
standard and 8 the blank. A 4-fold serial dilution was prepared of the reconstituted standards 
using the PCR 8-tube strip provided.  
Tubes were labelled Std1, Std2, Std3, Std4, Std5, Std6 and Std7; then, 200 μL of the 
reconstituted antigen standards was added to the first tube, i.e. Std1 of the strip of tubes. 150 
μL of sample type specific standard buffer was added to Std tubes 2-7. Universal Assay Buffer 
was used for serum or plasma samples and cell culture media for culture supernatant samples. 
50 μL of the reconstituted antigen standards was transferred from Tube 1 into Tube 2, mixing 
by pipetting up and down for a total of 10 times. 50 μL of the mixed standards from Tube 2 
was transferred into Tube 3 and mixed by pipetting up and down for a total of 10 times. This 
 72 
was repeated for Std tubes 4-7. Next, 200 μL of Universal Assay Buffer or cell culture medium 
was added to tube 8, which served as a blank and was kept on ice until ready for use. 
Table 2-11: Preparation of 4-Fold Serial Dilution 
 




          1/4        1/16 1/64 1/256 1/1024 1/4096 Blank 
Volume 
(µL) 
200 DSM B 
50 Std01+ 150 
UAB 
50 Std02 + 
150 UAB 
50 Std03 + 
150 UAB 
50 Std04 + 
150 UAB 
50 Std05 + 
150 UAB  






E. Define the plate map. 
 The standard, sample and blank wells were marked using the recommended and blank plate 
layout (Table 2-12). 
Table 2-12:  The plate map layout 
 
F. Preparing the capture bead mixture 
The capture bead bottles were vortexed for 30 seconds. The flat-bottom 96-well black plate 
provided in the kit was installed on the Hand-Held Magnetic Plate Washer (HHMPW), making 
 73 
sure it was securely attached (firstly the right side was installed followed by the left, and the 
mobile clip was adjusted to securely attach the plate onto the platform). 5 mL of each capture 
bead bottle provided in the kit was pipetted into a 50 mL tube. The capture bead mixture was 
transferred into a multichannel pipette reservoir. The appropriate amount of capture bead 
mixture was dispensed into each well of the plate. 50 µL was dispensed for each bead bottle 
used in the final mixture. Hence, for a kit containing 4 different bottles of magnetic beads, 4 x 
50 = 200 µL was dispensed into each well of the plate. The black plate cover was placed to 
protect the beads from the light and 2 minutes were allowed for the beads to become 
magnetically attached to the bottom of the wells.  
Making sure the plate was properly installed in the HHMPW, the liquid in the wells was 
discarded by quick inversion in the sink (one or two pulses) and the plate was blotted on a 
paper towel. The magnetic beads remained attached to the bottom of the wells. A new 
multichannel pipette reservoir was prepared with wash buffer (the reservoir was labelled using 
a marker pen). This reservoir could be washed and reused in further experiments. To wash the 
capture beads once, 150 µL of washing buffer was added to all the wells and the plate was 
covered to protect the beads from the light (cover was provided). The plate-HHMPW was 
rested on the lab bench for 2 minutes. Making sure the plate was properly installed in the 
HHMPW, the liquid in the wells was discarded by quick inversion in the sink (one or two 
pulses) and the plate was blotted on a paper towel. The magnetic beads remained attached to 
the bottom of the wells. 
G. First incubation (capturing the cytokines) 
Serum and plasma samples were diluted 1:2 by adding UAB to the wells (30 µL) and mixed up 
and down with the multichannel pipette. Standard and culture supernatant samples did not need 
diluting. 50 µL of all samples (diluted serum, diluted plasma and supernatants) were dispensed 
into the appropriate wells on the black plate. Duplicate analyses were done for the standards 
and single for the test samples. The plate was sealed with an adhesive slip (provided by the kit) 
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and covered to protect the beads from the light (cover usually provided, otherwise aluminium 
foil can be used). The plate was then detached from the HHMPW platform and incubated for 
1-2 h in the shaker at room temperature in the dark. It was ensured that the plate was securely 
fixed to the shaker using autoclave tape. The plate was taken from the shaker and installed on 
the HHMPW platform, waiting 2 minutes to allow the beads to become magnetically attached 
to the bottom of the wells.  
The seal was carefully removed and, making sure the plate was properly installed in the 
HHMPW, the liquid in the wells was discarded by quick inversion in the sink (one or two 
pulses) and the wells were blotted on a paper towel. The magnetic beads remained attached to 
the bottom of the wells. After washing the plate twice after the first incubation, 150 µL of 
washing buffer was added to all wells and the plate was covered to protect the beads from the 
light.  The plate-HHMPW was rested on the lab bench for 30 seconds. Making sure the plate 
was properly installed in the HHMPW, the liquid on the plate was discarded by quick 
inversion in the sink (one or two pulses) and the plate was blotted on a paper towel. The 
magnetic beads remained attached to the bottom of the wells.  
H. Second incubation (adding the biotinilated detection antibodies) 
3 mL of the detection antibodies mixture (1x) was prepared: The bottles (4 bottles: B, C, D and 
F) were briefly spun down. In a 15 mL conical tube, 60 µL of each bottle was dispensed and 
3000 – (60 x 4) = 2760 µL of detection antibodies diluent was added. This was gently vortexed 
and the detection antibodies mixture was transferred to a multichannel pipette reservoir. The 
plate was removed from the HHMPW platform and 25 µL of the mix was added to all wells 
without mixing (tips were changed each time). The plate was sealed with an adhesive slip 
(provided by the kit) and covered to protect the beads from the light. The plate was detached 
from the HHMPW platform and incubated for 30 minutes on the shaker at room temperature in 
the dark. The plate was securely fixed to the shaker using autoclave tape. After removing the 
plate from the shaker it was installed on the HHMPW platform for 2 minutes to allow the 
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beads to become magnetically attached to the bottom of the wells. The seal was carefully 
removed, and the plate was washed twice after the second incubation; 150 µL of washing 
buffer was added to all wells and the plate was covered to protect the beads from the light 
(cover usually provided).  
The plate-HHMPW was rested on the lab bench for 30 seconds and, making sure the plate was 
properly installed in HHMPW, the liquid on the plate was discarded by quick inversion in the 
sink (one or two pulses) and the plate was then blotted on a paper towel. The magnetic beads 
remained attached to the bottom of the wells.  
I. Third incubation (Adding Streptavidin-PE antibodies) 
The SA-PE antibody was transferred to a new multichannel pipette reservoir and plate from the 
HHMPW platform. 50 µL SA-PE antibody was added to all wells without mixing and by 
changing the pipette tips every time.  
The plate was sealed with an adhesive slip (provided by the kit) and covered to protect the 
beads from the light (cover usually provided, otherwise aluminium foil can be used). The plate 
was detached from the HHMPW platform and incubated for 30 minutes on the shaker at room 
temperature in the dark. The plate was securely fixed to the shaker using autoclave tape. After 
removing the plate from the shaker it was installed on the HHMPW platform for 2 minutes to 
allow the beads to become magnetically attached to the bottom of the wells. The seal was 
carefully removed, and the plate was washed twice after the third incubation; 150 µL of 
washing buffer was added to all wells and plate was covered to protect the beads from the light 
(cover usually provided).  
The plate-HHMPW was rested on the lab bench for 30 seconds and, making sure the plate was 
properly installed in HHMPW, the liquid on the plate was discarded by quick inversion in the 
sink (one or two pulses) and the plate was then blotted on a paper towel. The magnetic beads 
remained attached to the bottom of the wells.  
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J. Preparing the plate for reading on the Luminex instrument 
120 μL of reading buffer was added into each well. The plate was sealed with a new plate seal, 
covered with the black microplate lid and incubated 5 min on a plate shaker at RT at 500 rpm. 
After removing the seal the plate was run on a Luminex Instrument. The concentration of the 
samples was calculated by plotting the expected concentration of the standards against the MFI 
generated by each standard.  
2.13 RNA preparation for microarray analysis 
For preparation of microarray samples there are two methods of RNA purification that are 
commonly used. Method (I) is well established and is commonly used by Affymetrix users. 
Method (II) is a shortened derivative of Method (I) and has been used by MUSC DNA 
microarray users with good success.  
- Method (I). This involved purifying the RNA using Trizol according to manufacturer 
recommendations. The resulting RNA was taken and purify the RNA further using Qiagen 
RLT buffer as this may increase GeneChip background. 
- Method II. Trizol/RNeasy hybrid protocol. This method begins with Trizol homogenization 
and extraction. After this, the aqueous phase (containing the RNA) is combined with 70% 
ethanol and loaded onto an RNeasy column. Purification proceeds as described in Qiagen 
protocols (Cat No./ID: 74104, Germany). This method has the advantage of being simple and 
relatively short. It also limits handling of the RNA, perhaps reducing degradation. 
Method (II) has been used in this project (Trizol/RNeasy hybrid protocol). 
Adapted from communication by Alvydas Mikulskis, an appropriate volume of Trizol, Store 
homogenate at RT of 5 min.  
 77 
2.13.1 Total RNA isolation 




 cells were resuspended in 1 ml of Trizol (Invitrogen) 
and vortexed vigorously. These pellets were either stored at -80 
◦
C or the samples were 
processed immediately by incubating at RT for 5 min. The homogenised samples were mixed 
with 200 µl of chloroform and then centrifuged at 12,000 xg for 15 min at 4
◦
C. The separated 
upper aqueous phase was transferred into a fresh tube.  500 µl of 2-Propanol was added to the 
aqueous phase and the mixture was incubated for 10 min at RT. The samples were centrifuged 
at 12,000 xg for 10 min at 4
◦
C. The supernatant was discarded, and the RNA pellet was washed 
with 1000 µl of 75% (v/v) ethanol at 7500 xg for 5 min. The supernatant was discarded, and 
the RNA pellet was air-dried for 10-15 min. The pellet was dissolved in 30 µl of RNase free 
water and the concentration was determined using Thermo Scientific Nanodrop 
sphectrophotometer. Alternatively, RNeasy Micro Kit - RNeasyMinElute Spin Columns were 
used for purification of concentrated total RNA when dealing with small numbers of cells as 
per manufacturer’s instructions. 
2.14 Gene Expression 
(Jaksik et al., 2015), Provides a good overview of the Microarray Analysis from RNA 
extraction through to Data Processing. The microarray protocol is also described in Mesnage et 
al (2017). Below is a brief summary of the work;  
RNA extraction was performed using the MagMAX (Thermo-Fisher catalog number: 
AM1839) and Agencourt RNAdvance Cell V2 kit (Part number: A47942) according to the 
manufacturer's instructions. The samples were checked for RNA quality using the Agilent 
2100 Bioanalyzer Pico kit (Cat no: 5067-1513) and quantified using the Nanodrop (ND-1000 
Spectrophotometer). Samples with RNA intergrity number (RIN) of higher than 7 were 
selected for the microarray study. 500 pg of total RNA was used per sample. Poly-A Spiking 
Control (Thermo-Fisher 900433) was used as an internal amplification control. SPIA cDNA 
was generated usingNuGenOvation Pico WTA System V2 kit (Cat.no:3302-60), following the 
 78 
manufacturer's instructions. The SPIA cDNA was subjected to a quality control (QC) using the 
Agilent 2100 Bioanalyzer Nano kit (5067-1511) and quantified by Nanodrop ND-1000 
Spectrophotometer. The 5ug of SPIA cDNA was fragmented and Biotin-labelled using the 
NuGen Encore Biotin Module (Cat. no: 4200-60) according to the manufacturer's instructions. 
The fragmented and Biotin-labelled cDNA was subjected to a further round of QC to assess 
fragmentation size (Agilent 2100 Bioanalyzer Nano kit; fragment size < 200nt). 
 Hybridization cocktails were prepared according to Nugen's recommendations for midi arrays 
(100 format) (Encore Biotin Module User Guide Appendix) and Human Gene 2.0 ST Arrays 
(Thermo Fisher, 902113) were hybridized at 45oC for 16-20 hours in an Affymetrix Genechip 
Hybridization oven 645 (Cat no: 0-0331). The arrays were washed and stained using wash 
protocol FS450_0002 as recommended by Affymetrix, (Thermo Fisher) on the GeneChip 
Fluidics station 450. The arrays were scanned using the Affymetrix GeneChip Scanner. CEL 
files were quality control assessed in the Expression Console software package (Affymetrix, 
Thermo FIsher) by using standard metrics and guidelines for the Affymetrix microarray 
system. Data were normalised together using the Robust Multi-array Average (RMA) sketch 
algorithm. The study was performed in 3 separate groups (roughly 28 x 3) (Mesnage et al., 
2017). 




RNase free water Qiagen 
Phase lock Gel Heavy 2 ml 5 PRIME 







2.15 Expression microarray data analysis 
Gene expression analysis was done under the guidance of Dr. Shahram Kordasti. The HT 2.0 
arrays were scanned using a GeneChipR 3000 Scanner (7G upgrade) to capture images (DAT 
files). The raw data from the DAT file is converted to CEL files (based on intensities). 
ITERPLIER normalization was used to generate the CHP file. Ingenuity Pathway Analysis 
(IPA) was used to detect differential gene expression. In case of mutations, the gene expression 
in low-risk and high-risk MDS patients with the mutant was compared with that of healthy 
donors. The data was filtered using IPA p value ≤0.05 to create a list of significantly up or 
down regulated genes. 
2.16 Statistical analysis  
Data were entered into and analysed using Microsoft Excel and the results are presented as the 
mean ± standard deviation (SD). The data is normally distributed and analysis of variance 
between groups was performed using a parametric approach (one-way ANOVA and student T-
tests). P-values of < 0.05 were considered statistically significant. All statistical analysis was 
performed using GraphPad prism 6.0. (GraphPad Prism version 6.0 for Mac, GraphPad 









Chapter 3. Results I 
Comparative study of Complement Components, Regulators 
and Receptors in Healthy Donors vs. MDS Patients 
 
3.1  Introduction 
In this chapter the intracellular and surface expressions of the following complement receptors 
(C3aR, C5aR1 and C5aR2, CD46) in Tconv and Treg CD4
+
 T-cells from healthy donors, low-
risk and high-risk MDS patients were measured by flow cytometry. The expressions of 
complement components (C5a and C3a) were determined by Western blotting (WB). The 
results suggest that insufficient or excessive function and/or distribution of complement 
expression may partly contribute to inappropriate CD4
+
 T-cells activity in MDS.  
3.2 Gating strategy for flow cytometry analysis 
The Figures in 3-1 are from healthy, low-risk and high-risk MDS donors respectively; (A, C 
and E) representing cells from the control donors; i.e. non-activated, and (B, D and F) donors 











A: HD; non-activated B: HD; activated with anti-CD46 C: LR-MDS; non-activated 
D: LR-MDS; activated with anti-CD46 E: HR-MDS; non-activated F: HR-MDS; activated with anti-CD46 
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Figure 3-1: Showing the gating strategy in healthy donor (A and B), low-risk MDS (C and D) and 
high-risk MDS (E and F) donors. A, C and E cells were the control (non-activated) cells and B, D and 
F cells were activated with anti-CD46 antibody for 24 hours. The PBMCs were first gated for 
lymphocytes (SSC-A vs. FSC-A), singlet forward scatter dot plots (FSC-W vs. FSC- A), singlet side 
scatter dot plots (SSC-W vs. SSC- A) and the lymphocyte gate was further analysed for its uptake of the 
Live/Dead Aqua stain to determine live versus dead cells and their expression of CD3 and CD4, taking 
only the live, healthy T-cell population. CD4 surface expression was then determined from this gated 









) cells as appropriate. Expression of the proportion of Tregs in the CD4
+
 
lymphocyte gate was considered as an intercept of three gates based on the combination of staining cell 
surface markers (CD4, CD25, CD127) and intracellular staining of transcription factor forkhead box 
protein 3 (FoxP3). Histograms show a representative example of the expression of C3aR, C5aR1, 
C5aR2 (C5L2) and CD46 (numbers represent geometric mean fluorescent intensity), either on the 








 from healthy, low-risk MDS and high-risk 
MDS samples. A minimum of 10,000 events was collected per sample. Data were analysed using a 
FACS Canto II or Fortessa Flow Cytometer.  
 
3.3 Results 
3.3.1 Optimisation of test protocol 
Here I address the question of assessing complement receptor expression levels in CD4
+ 
T-
cells from PBMC samples taken from three different donor population: healthy donor (HD), 
low risk MDS (LR-MDS) and high risk MDS (HR-MDS). It was observed that there was no 
significant change in the intracellular expression of CD46 in Treg and Tconv cells in the 
presence or absence of anti-CD3 and CD46 at time points of 1 min and 1hr, and between 24 
and 48hr. This led to choosing the 24hr time point for subsequent experiments involving LR- 
and HR-MDS patients, owing to the low number of cells from these donors. 
3.3.2 Comparison of intracellular complement receptor expression in healthy vs 
MDS donors 
Following the protocol optimisation and the selection of the 24hr time point the activation of 
T-cells by the addition of anti-CD46 to PBMC, its ability to regulate intracellular complements 
expression was compared in healthy vs MDS donors. In all the Figures shown below, the left-
hand figures represent the means of the 10 donors in each treatment group while the right-hand 
figures represent the data for each individual in each treatment group. 
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3.3.3 Intracellular complement receptors expression in CD4+CD25high T-cells 
(Tregs) 
3.3.3.1 Intracellular complement receptors C5aR2 (C5L2) 
When PBMCs were stimulated with anti-CD3 plus anti-CD46 it was observed that Tregs in the 
HR-MDS group expressed significantly higher levels of C5a receptor 2 (C5aR2, C5L2) 
(Figure 3-2) than the HD (P=0.0042) and LR-MDS (P=0.003) groups. Thus, CD46 induced an 
upregulated C5L2 expression of Tregs in high-risk MDS patients. 
 
Figure 3-2: CD46 activation on high-risk MDS Treg cells induces intracellular C5L2 up-
regulation. 
PBMCs cultured in 48-well plates were activated for 24 h with mAbs anti-CD3, anti-CD3±CD28 or anti-
CD3±CD46 antibodies. Intracellular C5L2 expression in healthy donor, low-risk-MDS and high-risk MDS Treg 
cells was measured at different time points by FACS analysis. The data show the mean ± SD derived from healthy 
donor (n=10), low-risk MDS (n=10) and high-risk MDS (n=10) experiments.  
 
3.3.3.2 Intracellular CD46, C3aR and C5aR1 expression 
The data in Figure 3-S1 show the expression of MCP (CD46) in human Tregs in the three 
groups (HD, LR- and HR-MDS). Although the intracellular expression of CD46 in both the 
LR- and HR-MDS patients were lower than in the HD, there was no significant differences 
between the three-donor population (Appendix 1). Although not statistically significant, the 
expression of both C3aR (Figure 3-S2) and C5aR1 (Figure 3-S3) were higher in HR-MDS 

























































































































































Conditions (24 hours) 








3.3.4 Intracellular complement receptor expression in CD4+CD25-/low Tconv cells 
3.3.4.1 Intracellular expression of C3aR in human Tconv cells 
The expression of intracellular C3aR in T-conv cells in the HR group increased (Figure 3-3) 
compared to the both HD and LR-MDS donors. This increase was statistically significant in 
the HR-MDS vs HD groups pre- (P=0.0117) and post-stimulation (P=0.0027) with anti-CD3, 
anti-CD3+CD28 (P=0.0092) or anti-CD3+CD46 (P=0.0113).  
 
Figure 3-3: CD46 activation on high-risk MDS upregulates the intracellular C3aR expression. 
Intracellular C3aR expression of CD4+CD25- T-cells (Tconv) was monitored at 24 h by FACS analysis. Anti-
CD3/CD46 activated cells upregulate C3aR in HR-MDS. The data show the mean ± SD derived from HD (n=10), 
LR-MDS (n=10) and HR-MDS (n=10) experiments.  
 
3.3.4.2 Intracellular expression of C5aR1 in human Tconv cells 
CD4
+





 Tconv cells in the HR-MDS group compared to the LR 
(P=0.0009) and HD groups (P=0.0054) (Figure 3-4). Also, a significant difference was 
detected between the non-activated cells and those stimulated with anti-CD3+CD46 antibody, 
with C5aR1 being significantly expressed more in the activated cells compared to the non-



































































































Conditions (24 hours) 
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Figure 3-4: Post-CD46 activation of Tconv in high-risk MDS induces overexpression of 
intracellular C5aR1: 
PBMCs were activated for 24 h with an anti-CD3±CD46 antibody. The CD4+CD25
- 
T-cell (Tconv) intracellular 
C5aR1 expression was measured at the indicated time points. The data show the mean ± SD derived from ten 
experiments (n=10) for each group.  
 
3.3.4.3 Intracellular CD46 and C5L2 expression in human Tconv cells 
Here, no significant difference was found in the intracellular expression of CD46 (Figure 3-
S4) and C5L2 (Figure 3-S5) in Tconv cells between the three groups (HD, LR- and HR-MDS) 
(Appendix 1).  
3.3.5 Surface expression of complement receptors by Tregs 
3.3.5.1 Expression of C3aR on the surface of Treg 
The results demonstrated low surface expression of C3aR on Treg cells of the HR-MDS 
donors compared to the both HD and LR-MDS donors (Figure 3-5) with significant 
differences between the HR-MDS and HD samples after stimulation with anti-CD3 
(P<0.0001), anti-CD3+CD28 (P=0.0002) or anti-CD3+CD46 (P=0.0003). Also, there was low 
expression of C3aR in the Treg cells of the LR- group compared to the HD, with significant 
changes in the LR-MDS and HD groups before activation (P=0.0027) and after stimulation 
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Figure 3-5: Down-regulation of C3aR expressions on the surface of Treg. 
Surface C3aR expression on CD4+CD25high T-cells (Treg) was monitored at 24 h by FACS analysis. The results 
show low levels of C3aR expression on the surface of Tregs in LR- and HR-MDS. The data show the mean ± SD 
derived from healthy donor (n=5), LR-MDS (n=5) and HR-MDS (n=5) experiments.  
 
3.3.5.2 Expression of C5L2 on the surface of Treg 





Treg cells of LR- and HR-MDS patients compared to healthy donors, (P= 0.0045 and 
P=0.0022 respectively) (Figure 3-6).  
 
Figure 3-6: Expression of C5L2 on the surface of human Treg cells using FACS analysis. 
PBMCs were activated for 24 h with mAbs anti-CD3, anti-CD3±CD28 or anti-CD3±CD46 antibodies. Surface 
C5aR2 (C5L2) expression of healthy donor, low-risk-MDS and high-risk MDS Treg cells were then measured at the 
24 h time point by FACS analysis. The data show the mean ± SD derived from HD (n=5), LR-MDS (n=5) and HR-


























































































































































Conditions (24 hours) 




































































































































































Conditions (24 hours) 








3.3.5.3 Expression of CD46 and C5aR1 on the surface of Treg 
It was noticed that no significant change in the expression of CD46 (Figure 3-S6) and C5aR1 




 Treg cells in all three groups, although C5aR1 
expression was higher in HD compared to MDS donors (Appendix 1).  
3.3.6 Surface expression of complement receptors by Tconv 
3.3.6.1 Expression of CD46 on the surface of Tconv 
Figure 3-7 shows the expression of human MCP (CD46) on the surface of human Tconv cells 
in all three groups (HD, LR- and HR-MDS). There was high surface expression of CD46 in the 
HR-MDS patients compared to the HD and LR-MDS groups, and significant differences were 
found between levels of CD46 in the HR- and LR-MDS groups. Low surface expression of 
CD46 was recorded on the Tconv cells of the LR-MDS group just after stimulation with anti-
CD3 (P=0.042), anti-CD3+CD28 (P=0.0351) or anti-CD3+CD46 (P=0.0359) compared to HR-
MDS.  
 
Figure 3-7: MCP (CD46) expressions on the surface of human T-cells (Tconv) 
PBMCs were activated for 24 h with an anti-CD3, anti-CD3±CD28 or anti-CD3±CD46 antibodies. Surface CD46 
expression of Treg cells was measured at the 24 h time point. Results are representative of fifteen (n=15) 


























































































































































Conditions (24 hours) 









3.3.6.2 Expression of C5aR1 on the surface of Tconv 
The data showed low expression of C5aR1 in the Tconv cells of the LR-MDS group (Figure 
3-8).  The expression levels in both HD and HR donors were significantly higher (P=0.0009, 
0.027 respectively) than the LR donors when cells were stimulated with anti-CD3+CD46. On 
the other hand, no significant difference was noted in the surface expression of C5aR1 between 




Figure 3-8: C5aR1 expression on the surface of (Tconv). 
PBMCs were activated for 24 h with an anti-CD3±CD46 antibody. C5aR1 expression on the surface of Tconv cells 
was measured at the 24 h time point. The data show the mean ± SD derived from ten experiments (n=5) for each 
group.  
 
3.3.6.3 Expression of C5L2 on the surface of Tconv 
C5L2 expression on the surface of T-conventional cells of HD-MDS patients before and after 
stimulation with anti-CD3 (P=0.026), anti-CD3+CD28 (P=0.048) or anti-CD3+CD46 
(P=0.031) was markedly higher than that for the LR-MDS group (Figure 3-9). Very low 
expression was noticed on the surface of T-conv cells of LR-MDS patients before stimulation 































































































































































Conditions (24 hours) 














anti-CD3+CD46 (P=0.025) compared to the HD group (Figure 3-9). The expression levels 
were not significant between the HR-MDS and HD groups.  
 
 
Figure 3-9: C5L2 expression on the surface of Tconv cells 
T-cells were cultured in 48-well plates and then activated with mAbs to anti- CD3±CD46 antibody. C5L2 
expression was measured on the surface of Tconv at the time points shown by FACS analysis. The data show the 
mean ± SD derived from five experiments (n=5) for each group. 
 
3.3.6.4 Expression of C3aR on the surface of Tconv 
There was no significant difference in the surface expression of C3aR on Tconv cells between 
the three groups (Figure 3-S8), although the expression was higher in the HD (Appendix 1).  
Table 3-1: Summary of the results of intracellular and surface staining of complement receptors in 
Tregs and Tconv cells 
Complement 
receptor 
Intracellular staining Surface staining 
Treg Tconv Tregs Tcon 
CD46 ↑HD than LR & 
HR 
→ HD, LR & 
HR 
↑HD than LR & HR ↑↑HR than LR  
C3aR ↑HR than LR & 
HD 
↑↑HR than LR 
& HD 
↑↑HD than LR & HR ↑HR than LR & HD 
C5aR1 ↑HD than LR & HR ↑↑HR & HD than 
LR 
C5L2 ↑↑HR than LR 
& HD 
→ HD, LR & 
HR 
↑HD than LR & HR ↑↑HR & HD than 
LR 
↑ is high, ↑↑ is significantly higher; → is similar levels; HD: healthy donors; HR: high risk MDS; LR: 































































































































































Conditions (24 hours) 













3.4 CD4+ T-cell expression of complement component C3a+C5a by Western Blot 
To determine the expression of complement components (C5a and C3a), Western blotting was 
conducted. It was observed that in HD (two donor samples) the stimulation of CD4
+
 T-cells 
with anti-CD3+CD46 resulted in downregulation of both C5a (Figure 3-10) and C3a (Figure 
3-11) compared to non-activated or anti-CD3+CD28 stimulation. In both HR and LR-MDS 
donors (two samples for each) there was no expression of these two complement components 
in either the activated or non-activated state. The numbers below the Western blots represented 
the band intensity (quantification) for the healthy donors (Figure 3-10 and 3-11). For MDS 
samples, quantification could not be performed because there were no detectable bands. Image 
Studio Lite software was used for normalisation of band intensity. 
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Figure 3-10: Western Blot analysis for Complement Component (C5a). Western blot analyses of cell 
lysates from 24h activated CD4+ T-cells assessed for C5a (8.27-kDa) expression. Cells were left non-activated or 
activated with anti-CD3+CD28 or anti-CD3+CD46. β-actin levels (42-KDa) were measured as loading control. 
Precision plus protein dual extra prestained protein standards as a loading marker (2-250 KDa). Anti-human 
complement component C5a antibodies used as a positive control to only recognize a C5a molecular weight. Data in 
Figures A-C are representative of 2 independently performed experiments using a different donor each time A) 
Healthy donor B) HR-MDS and C) LR-MDS.  
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Figure 3-11: Western Blot analysis of C3a expression in CD4
+
 T-cells. Western blot analyses of cell 
lysates from 24h activated CD4+ T-cells assessed for C3a (9.1-kDa) expression. Cells were left non-activated or 
activated with anti-CD3+CD28 or anti-CD3+CD46. β-actin levels (42-KDa) were measured as loading control. 
Precision plus protein dual xtra prestained protein standards as a loading marker (2-250 KDa). Anti-human 
complement component C3a antibodies used as a positive control to only recognize a C3a molecular weight. Data in 
Figures A-C are representative of 2 independently performed experiments using a different donor each time A) 




In this study I compared the expression of intracellular and surface complement receptors 
(CD46, C3aR, C5aR1, and C5L2) in Treg and Tconv CD4
+
 cells in healthy versus low-risk and 
high-risk MDS patients. Additionally, complement component C3a and C5a expression, both 
of which are anaphylatoxins were determined. To do these, I initially optimised a protocol to 
determine the optimum time point for effective expression of these markers. I observed that 
culturing PBMC from healthy donors for a period of 24hr was ideal for the test protocol.  
For intracellular staining of complement receptors, I observed a significantly higher expression 
of C5L2 after stimulation with anti-CD3+CD46 in Tregs of HR-MDS donors than healthy and 
LR-MDS donors, and a significantly higher expression of both C3aR and C5aR1 in Tconv 
cells of HR-MSD than in healthy and LR-MDS donors. In contrast to the intracellular staining 





 Tregs cells of LR and HR-MDS patients compared to healthy donors.  On the 
other hand, the expression of C5L2 on the surface of Tconv cells of HR-MDS samples before 
and after stimulation with anti-CD3, anti-CD3+CD28 or anti-CD3+CD46 was markedly higher 





 Tregs have been observed in different autoimmune diseases (Astier 
et al., 2006). Complement signalling through C3aR and C5aR have been shown to inhibit 
Tregs expression and function through a C3a/C5a-induced phosphorylation of AKT 
phosphorylate (Le Friec et al., 2013). Other studies have also demonstrated that complement 
receptor signalling via interaction of CD4
+
 T-cells and dendritic cells up-regulates co-
stimulatory molecule expression, thus enhancing TH1 and TH17 T effector function and 
increasing the survival of Tconv cells (Strainic et al., 2013). Intracellular complement 
components are one of the key players in initiating and regulating T-conventional and T-
regulatory T-cell responses (Heeger and Kemper, 2012). The higher C5L2 expression in HR-
MDS donors in Tregs may result in inhibition of C3a and C5a and thereby making C3aR and 
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C5aR1 available for binding by Tconv cells. This result was confirmed by the output from a 
Western blot in which both HR-MDS and LR-MDS donors showed no expression of C3a and 
C5a complement components in both activated and non-activated states. Thus, C5a and C5aR 
signalling in CD4
+
 T-cells potentiate immune responses, while the absence of this signalling 
could convert naïve T-cells to an iTreg response (Strainic et al., 2013). Alternatively, it is 
possible that patients with MDS might have some defect in CD4
+
 T-cells and that might have 
accounted for their inability to express the two complement components (C3a and C5a). 
My findings have shown significantly high surface expression of CD46 in Tconv of HR-MDS 
patients compared to the HD and LR-MDS patients. This observation was so in both pre- and 
post-stimulation with anti-CD3, anti-CD3+CD28 or anti-CD3+CD46.  
With respect to surface staining, significant expression levels of complement receptor C3aR 
were observed in Tregs cells of HR-MDS patients compared to HD and LR-MDS patients. On 
the contrary, in Tconv cells, significant expression levels of three of the four complement 
components CD46, C5aR1 and C5L2 were observed in HR-MDS patients compared to HD and 
LR-MDS patients. The expression of C3aR is inducible under inflammatory conditions both in 
vitro and in vivo with T-cells from patients with signs of severe systemic inflammatory 
reactions noticeably expressing C3aR (Werfel et al., 2000). Additionally, the reduction of 
intracellular T-cell C3aR expression induces a decrease in mTOR activity and cell viability 
similar to that induced by the CSTL inhibitor, implying that intracellular C3a generation and 
C3aR ligation contribute to mTOR activity and overall T-cell survival (Clarke and Tenner, 
2014). Recently, some studies have reported the role of C5L2 in regulating inflammation 
(Chen et al., 2007). In addition, C5L2 has also been shown to contribute to signalling triggered 
by C5a or C3a with C5aR or C3aR (Chen et al., 2007). Intriguingly, it has been found that 
C5L2 may be critical in upregulating cell surface expression of C5aR, particularly in T-conv 
cells, which suggests that C5L2 is capable of transducing signals; this may be how C5L2 
contributes to C5a signal optimization. The absence of signalling via C3aR and C5aR resulted 
in the lower expression of co-stimulatory molecules and interleukin 6 (IL-6) and more 
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production of IL-10. The resulting iTreg cells exerted robust suppression, showed enhanced 
stability, and suppressed ongoing autoimmune disease. Antagonism of C3aR and C5aR can 
also induce functional human iTreg cells (Strainic et al., 2013). Additional studies exhibited 
that signalling through C5L2, and not C5aR, leads to inflammatory protein release and thus the 
proinflammatory role of C5L2 is posited (Bamberg et al., 2010). C5L2 becomes activated only 
after C5aR and ligand binding, thus functioning as an intracellular receptor.  
3.6 Perspective 
Collectively, in this study I observed no expression of C3a and C5a, subsequent lack of 
signalling through C3aR and C5aR along with upregulation of C5aR2 (C5L2), an alternative 
receptor for C5a, in MDS patients suggesting a potential mechanism for Treg expansion in 
MDS. Moreover, the contribution of C5L2 in regulating pro-inflammatory and anti-
inflammatory responses and, in particular, certain features of the complement signalling 
pathway, makes it a possible agent for remedying diseases such as MDS. The next chapter will 
examine levels of complement associated mTOR and TGF-β signalling pathway-associated 
proteins in healthy donors and patients with LR- and HR-MDS.  
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Chapter 4. Results II                                                          
Levels of mTOR, TGF-β Signalling Pathway-Associated 
Proteins, and Cytokines in Patients with MDS 
 
4.1 Introduction 
Intracellular complements (particularly C3a and C5a) play a crucial role in the polarization of 
CD4
+
 T-cells toward regulatory or effector phenotypes through the TGF-β pathway (C5aR2 
mediated) or mTOR (C5aR1 mediated) respectively. However, the C5L2 expression and its 
relationship with Treg suppressor function and stability are not known. To address the current 
knowledge gap, I sought to explore whether the stimulation of complement receptors (C3aR, 
C5aR) with exogenous C3a and C5a may lead to the hyper-activation of the mTOR pathway 
instead of the SMAD signalling pathway and any potential increases in the number of Th1 
cells. The aim of this present chapter is to investigate the potential role of mTOR and Akt as 
important proteins in complement-related polarization of CD4
+
 T-cells towards pro-
inflammatory T helper cells MDS. The TGF-β signalling pathway and its related proteins were 
also studied which are activated following stimulation with anti-CD46 antibody in CD4
+
 T-
cells from healthy donor (HD), LR and HR-MDS patients. Furthermore, responses following 
treatment with C3a and C5a were examined. Also, the supernatant concentrations of cytokine 







4.2.1 The role of complements components in levels of mTOR and TGF- β 
signalling Pathway-Associated Proteins in Patients with MDS 
TGF-β signalling pathway proteins pSMAD2, pSMAD3 and pSMAD4 as well as mTORc 
were evaluated in human CD4
+
 T-cells of 6 healthy donors and 12 MDS patients (out of which 
6 had LR and 6 had HR-MDS).  
4.2.1.1 mTOR  
Regarding mTOR signalling pathway, CD46 induced a significant down-regulation of pmTOR 
levels in HR-MDS patients. Before the treatment with C3a+C5a, the levels of pmTOR 
decrease in the HR-MDS (P=0.0278) as compared to healthy donors. While, after treatment 
with C3a and C5a, the levels of pmTOR in the HR-MDS (P=0.0441) increased slightly but 
were still not to the level as in the HD. Although the level of pmTOR is downregulated in LR-
MDS after stimulation with CD46, the data show no significant decrease in protein levels of 
mTOR as compared to HD (Figure 4-1).  
 
Figure 4-1: mTOR expression following CD4
+
 T-cell stimulation and C3a+C5a treatment. 
CD4+ T-cells, from healthy (n=6), LR-MDS (n=6) and HR-MDS donors (n=6) without (−) or with (+) stimulation 
(anti-CD3/28) or (anti-CD3/46) and with absence (−) or with presence (+) of 50nM C3a and C5a of each. Error bars 
































































































































































































































































































































































4.2.1.2 pSMAD 2, 3 & 4 
Following stimulation with anti-CD3±CD46 for 24 hours, CD4
+
 in HR-MDS patients showed 
a significantly lower level of pSMAD2 (p=0.016) (Figure 4-2), pSMAD3 (p=0.0110) (Figure 
4-3) and pSMAD4 (p=0.0017) (Figure 4-4) in comparison to HD. However, in pSmad2 
following CD46 stimulation, the combination of C5a and C3a induced an increase in pSmad2 
levels (p=0.0442) in HR-MDS compared to HD (Figure 4-2). In HR-MDS patients the level of 
pSMAD4 increased after 24 hours of stimulation with anti-CD3 and CD46 plus C3a and C5a 
(p=0.027) (Figure 4-4) compared to HD. Moreover, in HR-MDS patients the level of 
pSMAD3 (p=0.0258) remained significantly lower than LR-MDS after 24 hours of stimulation 
with anti-CD3 and CD46 plus C3a and C5a (Figure 4-3). However, no noticeable changes 
were noted in the protein levels of p-SMAD3 (Figure 4-3) and p-SMAD4 (Figure 4-4) were 
seen between the HD and LR-MDS. In p-SMAD4 there was a significant difference between 
the HR and LR-MDS patients (p=0.0005) when activated with anti-CD3+CD46. 
 
 
Figure 4-2: pSMAD2 signalling in HD, LR and HR-MDS  
Naïve CD4+ T-cells isolated from PBMCs of healthy (n=6), LR-MDS (n=6) and HR-MDS (n=6) donors without (−) 
or with (+) stimulation (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with presence (+) of C3a 50nM and 






























































































































































































































































































Figure 4-3: p-SMAD3 protein levels 
CD4+ T-cells from healthy, LR-MDS and HR-MDS donors were left inactivated or activated for 24 h with mAbs 
anti-CD3, anti-CD3+CD28 or anti-CD3+CD46 antibodies and cells were untreated or treated with 50nM C3a and 
50nM C5a. The data show the mean ± SD derived from HD (n=6), LR-MDS (n=6) and HD MDS (n=6) 




Figure 4-4: Defect in pSMAD4 signalling in HR-MDS after stimulation.  
CD46 without C3a+C5a downregulated pSMAD4 and CD46 plus C3a+C5a up-regulated it in naïve CD4+ of HR-
MDS cells compared to healthy and LR-MDS cells. Error bars indicate SD of six experiments. Data are 




































































































































































































































































































































































































































































































































4.2.1.3 pAKt, pERK1/2 and TGFbRII 
In pAKt, independent of the culture condition, there was no significant difference in fold 
change between HD, HR and LR-MDS (Figure 4-S1) Appendix 2. 
The protein level of pERK1/2 showed decrease in LR-MDS compared to HD and HR-MDS. 
PERK1/2 was down-regulated by CD3+CD46 alone and up-regulated in the presence of C3a 
and C5a except in LR-MDS which had no response after C5a and C3a treatment. However, no 
noticeable changes in the protein levels of p-ERK1/2 were found between HD and HR-MDS 
patients (Figure 4-S2) Appendix 2. 
Finally, the protein levels of TGFbRII showed no significant changes between HD, LR and 











4.2.2 Cytokine secretion in response to stimulation to complement pathway 
stimulation 
The aim of this part of study was to evaluate the cytokine secretion by CD4
+ 
T-cells from MDS 
patients in response to complement pathway activation. Supernatants from the culture 
conditions were used for the cytokine assays. It was observed that IL-17A secretion induced by 
anti-CD3, anti-CD3+CD28, anti-CD3+CD46 co-activation in CD4
+
 T-cells was increased 
significantly in LR-MDS patient (from about 1.0 to 1.5 pg/cells ×10
3
) compared with HR-
MDS (P=0.00660) after complement treatment, and both before and after complement 
activation (Figure 4-5) compared to HD (P=0.0088, 0.0202 respectively) (Table 4-1).  
 
Figure 4-5: IL-17A secretion by CD4
+
 T-cells in LR-MDS, HR-MDS and HD.  
Isolated naïve CD4+ T-cells from PBMCs of healthy (n=3), LR-MDS (n=3) and HR-MDS (n=3) donors were 
maintained non-activated or activated with CD3 alone, (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with 
presence (+) of 50nM C3a and C5a for 24h for each. Then the supernatants were collected, and the concentrations 

























































































































































































































Table 4-1: Summary of the results of cytokines (IL-17A, IFN-γ, IL-6 and IL-2) (P-value) in HD, LR and HR MD. Red boxes (increased) values. 
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Amongst the pro-inflammatory cytokines secreted by activated CD4
+
 T-cells, it was observed 
that IFN-γ was significantly over produced in all the conditions of activation in LR-MDS 
compared to HR-MDS and HD (Table 4-1). IFN-γ concentrations induced by anti-CD3+CD46 
co-activation was significantly over secreted in patients with LR-MDS compared to HR-MDS 
(P=0.005) and HD (P=0.0029) (Figure 4-6). IFN-γ secretion rates were 10-20 times over-
produced in the LR-MDS patients compared to HD and HR-MDS patient groups. The IFN-γ 
secretion levels were slightly higher in HR-MDS patients compared to HD, but the difference 
did not reach statistical significance by activated CD4
+
 T-cells. The level of IFN-γ secretion in 
LR-MDS did not change after CD3+CD46 co-activation plus C3a+C5a treatment (Figure 4-6).  
 
Figure 4-6: IFN-γ secretion by CD4+ T-cells in LR-MDS, HR-MDS and HD. 
Isolated naïve CD4+ T-cells from PBMCs of healthy (n=3), low-risk MDS (n=3) and high-risk MDS (n=3) donors 
were maintained non-activated or activated with CD3 alone, (anti-CD3/28) or (anti-CD3/46) and with absence (−) 
or with presence (+) 50nM C3a and 50nM C5a for 24 h. Then the supernatants were collected, and the 
concentrations of secreted cytokines were measured. Error bars indicate SD of three experiments. Data are 


























































































































































































































































































































 T-cells from LR-MDS patients compared to HD, before and after CD3, 
CD3+CD28 and CD3+CD46 co-activation (Table 4-1). The levels of IL-2 were slightly 
decreased in cells from HR and LR-MDS after anti-CD3+CD46 co-activation plus 
complement treatment (Figure 4-7). 
 
Figure 4-7: Isolated CD4
+
 T-cells IL-2 secretion profiles 
Isolated naïve CD4+ T-cells from PBMCs of healthy (n=3), LR-MDS (n=3) and HR-MDS donors (n=3) were 
maintained non-activated or activated with CD3 alone, (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with 
presence (+) of C3a (50nM) and C5a (50nM) for 24 h. Then the supernatants were collected, and the concentrations 
of secreted cytokines were measured. Error bars indicate SD of three experiments. Data are representative of three 
experiments with similar results. 
 
Figure (4-8), demonstrate that CD4
+
 T-cells from patients with LR and HR-MDS have higher 
IL-6 concentration rates than HD, both when non-activated and also after CD3, CD3+CD28 
(Table 4-1). After CD3+CD46 stimulation the level of secretion of IL-6 was significantly 

















































































































































































































































































































Also, it was noted that there was a decrease in IL-6 levels from CD4
+
 T-cells in patients with 




 T-cells IL-6 secretion in LR-MDS, HR-MDS patients and HD is altered by 
complement treatment. 
Isolated naïve CD4+ T-cells from PBMCs of healthy (n=3), LR-MDS (n=3) and HR-MDS (n=3) donors were 
maintained non-activated or activated with CD3 alone, (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with 
presence (+) of 50 nM C3a and C5a (for each) for 24 h. Then the supernatants were collected and the concentrations 
of secreted cytokines were measured. Error bars indicate SD of three experiments. Data are representative of three 
experiments with similar results. 
 
It was noticed that there was a significant tendency for IL-18 to be over-produced (3-6 folds) 
in CD4
+
 T-cells from LR-MDS patients compared to HD and HR-MDS, after anti-CD3, anti-
CD3+CD28 and anti-CD3+CD46 co-activation (Table 4-2). The levels of IL-18 were slightly 









































































































































































































































































































P* = 0.0428 
P* = 0.0352 
P***= 0.0008 
P* = 0.0153 
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Figure 4-9: IL-18 secretion by CD4
+
 T-cells in LR-MDS, HR-MDS and HD.  
Isolated naïve CD4+ T-cells from PBMCs of healthy (n=3), LR-MDS (n=3) and HR-MDS (n=3) donors were 
maintained non-activated or activated with CD3 alone, (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with 
presence (+) of 50 nM C3a and C5a (For each) for 24 h. Then the supernatants were collected and the 
























































































































































































































































































































In all the conditions of activation, IL-1RA secretion was a significant higher (15-20 times) in 
HR-MDS patients compared to LR-MDS and HD (Table 4-2). The level of IL-1RA 
concentration was slightly increased in cells from the HR-MDS group after the combination of 
C3a+C5a treatment (Figure 4-10). 
 
 
Figure 4-10: Isolated CD4
+
 T-cells IL-1RA secretion higher in HR-MDS patients. 
Isolated naïve CD4+ T-cells from PBMCs of healthy (n=3), LR-MDS (n=3) and HR-MDS (n=3) donors were 
maintained non-activated or activated with CD3 alone, (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with 
presence (+) of 50 nM C3a and C5a (for each) for 24 h. Then the supernatants were collected, and the 
concentrations of secreted cytokines were measured. Error bars indicate SD of three experiments. Data are 





















































































































































































































































































































TNF-α secretion patterns were analysed and it was found that in all conditions of activation, 
the level of TNF-α were significant over produced in LR-MDS compared to HD (Table 4-2). 
TNF-α concentration rates were 15-20-fold higher in LR-MDS compared to HD and around 5-
10 times higher compared to HR-MDS after anti-CD3+CD28 co-activation. There was no 
significant response noted for TNF-α secretion after complement treatment in CD4+ T-cells of 




 T-cells pro-inflammatory (TNF-α) secretion patterns is higher in LR-MDS 
patients. 
Isolated naïve CD4+ T-cells from PBMCs of healthy (n=3), low-risk MDS (n=3) and high-risk MDS (n=3) donors 
were maintained non-activated or activated with CD3 alone, (anti-CD3/28) or (anti-CD3/46) and with absence (−) 
or with presence (+) 50nM C3a and 50 nM C5a for 24 h. Then the supernatants were collected, and the 
concentrations of secreted cytokines were measured. Error bars indicate SD of three experiments. Data are 



















































































































































































































































































































Finally, IL-10 secretion from activated CD4
+
 T-cells was significantly over-secreted in LR-
MDS patients after anti-CD3, anti-CD3+CD28 and anti-CD3+CD46 activation (Table 4-2). 
CD4
+
 T-cells from LR-MDS cells were secreted IL-10 (32-35 times) more than of HD. As 
expected, anti-CD3+CD46 co-activation increased IL-10 secretion in HR-MDS as well as LR-
MDS cells, with a slightly response in HR-MDS and no response in LR-MDS following 
complement treatment (Figure 4-12). 
 
 
Figure 4-12: Isolated CD4
+
 T-cells pro-inflammatory (IL-10) secretion patterns is over-secreted in 
LR-MDS patients. 
Isolated naïve CD4+ T-cells from PBMCs of healthy (n=3), LR-MDS (n=3) and HR-MDS donors (n=3) were 
maintained non-activated or activated with CD3 alone, (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with 
presence (+) of C3a and C5a 50 nM for each (for 24 h). Then the supernatants were collected, and the 
concentrations of secreted cytokines were measured. Error bars indicate SD of three experiments. Data are 































































































































































































































































































































In this chapter I observed both mTOR and other TGF-β signaling Pathway-Associated Proteins 
(pSMAD2, pSMAD3, pSMAD4) were significantly reduced in HR-MDS patients relative to 
HD and LR-MDS patients. This might be associated with a defect in the CD4
+
 T-cell 
signalling pathway. TGF-β is an important physiologic regulator of cell growth and 
differentiation.  Previous work has revealed the roles of C3a and C5a, which bind to their 
receptors on T-cells. Kolev, Dimeloe, Le Friec et al. (2015) have provided evidence for a 
function of the C3b-binding protein CD46 in the enhancement and sustainment of signalling to 
mTORC1 as part of the mechanisms by which complement components are able to regulate 
functional characteristics of T-cells (Boothby et al., 2015). Other studies have demonstrated 
that conventional and regulatory T-cell subsets are altered by complement components acting 
directly on T-cells.  
With reference to cytokine role, there were significant increases in the levels of IL-10, IL-17, 
IL-18, IFN-γ and TNF-α, and high levels of IL-2 in LR-MDS patients compared to HD and 
HR-MDS patients. IL-1RA and IL-6 were the only cytokines significantly elevated in HR-
MDS patients relative to HD and LR-MDS patients. CD46 shares a phenotype with Tr1 cells; 
it can induce low IFN-γ and high IL-10 in naïve CD3-activated CD4+ T-cells (Cardone et al., 
2010). Therefore, CD46 plays a significant role in the regulation of adaptive immunity 
regulation and its deficiency has associations with autoimmune diseases and chronic 
inflammation (Kemper and Atkinson, 2007). The principal Th1 cytokine, IFN-γ, is produced 
by CD4
+
 T-cells (Abramson et al., 2001). However, it was interesting to observe that the levels 
of IFN-γ secretion in LR-MDS was not change following CD3+CD46 co-activation plus 
C3a+C5a treatment. These results suggest a negative correlation in LR-MDS patients: IFN-γ 
secretion is increased by anti-CD3, anti-CD3+CD28 and anti-CD3+CD46 activated CD4
+
 T-
cells and no effect by complement treatment. Several types of immune cells secrete IL-6, 
including Th2 lymphocytes. Moreover, IL-17A acts on a variety of cells to induce cytokine 
such as IL-6 and TNF-α (Fossiez et al., 1996). CD4+ T-cells from patients with LR and HR-
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MDS have higher IL-6 concentration than HD when non-activated and also after CD3, 
CD3+CD28 and CD3+CD46 stimulation. High levels of IL-6 in HR-MDS patients could 
account for the dysregulation of CD4
+
 T-cell activation and induction. Moreover, complements 
have an important influence in the promotion of the function, activation and induction of CD4
+
 
T-cells in MDS patients. 
IL-2 is produced mainly by activated Th1 cells and is an important immune response and 
homeostasis regulator. It also plays a pivotal role in the downregulation of immune response, 
for example its absence often results in severe autoimmunity (Malek, 2008). This could be 
related to deleterious biomaterial interactions, which promote activation of signaling pathways 
inducing pro-inflammatory cytokine secretion in CD4
+
 T-cells.  
TNF-α is a pro-inflammatory cytokine produced by Th1 cells that promotes several 
autoimmune diseases. IL-10 inhibits the production of IFN-γ, TNF-α and IL-2. A study by 
Mallat et al. has presented findings to verify the anti-inflammatory and immunosuppressive 
activity of IL-10 (Mallat et al., 1999). Nevertheless, it is still uncertain whether high plasma 
levels of IL-10 are to be measured as a marker of anti-inflammatory patterns or conversely 
whether they are counter-regulatory outcomes related to primitive pro-inflammatory patterns 
(Heeschen et al., 2003). Another major source of IL-10 is CD4
+
 Treg cells, thus the increased 
IL-10 secretion in LR-MDS patients’ co-activated T-cells could reflect an effort of these cells 
to shift from IFN-γ to IL-10 secretion; from a Th1 to a Treg phenotype (progressing the 
disease from LR to HR-MDS). However, the high levels of IFN-γ observed in the same 
condition imply that this transition, which is essential for the regulation of innate and adaptive 
immune response, does not occur.  
The findings here provide the first evidence that complement regulates CD4
+
 T-cells by 
directly affecting the fate and properties of these cells. The results establish that defects in the 
TGF-β signalling pathway proteins (pSMAD2, pSMAD3 and pSMAD4) as well as mTORc 
and no or low response to complement treatment contribute to CD4
+
 T-cell dysfunction and 
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irregularities in cell fate response in MDS patients. Therefore, complements, TGF-β signalling 
pathway proteins, and mTOR represent potential therapeutic targets for improving MDS 
therapy. Finally, no single treatment is effective for all patients with MDS due to its biologic 
heterogeneity. With more detailed knowledge of cytokine signalling cascades, together with 
technological developments in genomics and proteomics, the future treatment of MDS may lie 
in combination therapies tailored for appropriate biological effectors.  
4.4 Perspective 
While this data suggests a possible connection between complement and T-cells, the cytokine 
data is not sufficient to make a definitive conclusion. This was the reason for carrying out the 
phenotyping and WB assays before and after anti-CD46 stimulation (as shown in the previous 
chapter). Furthermore, the results of the mTOR and TGF-beta proteins levels following 
complement support the above hypothesis. Jointly, this chapter demonstrate that the mTORc 
protein level in HR-MDS is reduced and does not change in response to complement 
components or to receptor stimulation, and neither does the level of Akt. This may prevent 
CD4
+
 T-cells polarizing towards pro-inflammatory T-cells (Th1 or Th17) therefore averting an 
effective immune-surveillance against malignant clones. Lack of response to complement 
related co-stimulation and increase in C5aR2 expression indicate a potential mechanism for 
Treg expansion in MDS. Overexpression of pro-inflammatory cytokines is strongly associated 
with LR-MDS. These findings may lead to novel therapeutic targets being identified in MDS, 
although further studies are needed on a larger cohort of patients. Moreover, these data show 
that complement components may modulate cytokine and chemokine-induced differentiation 
and activation of CD4
+
 T-cells, possibly through TGF-β regulation.   
To confirm this I will estimate the gene expression of T-cells before and after anti-CD46 
stimulation following two conditions i.e. in the presence or absence of complement 
(C3a+C5a).  
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Chapter 5. Results III 




In this chapter I have used an analytical approach to investigate the differential gene 
expression profiles of T-cells in MDS and HD following stimulation with anti CD46 with or 
without complement components C3a+C5a. Whiles I focused on the specific complement 
related pathways in the previous chapters, in this chapter I wanted to determine the 
involvement of other pathway, if any, following the stimulation of Tconv or Tregs CD4
+
 T-
cells with anti-CD46 using gene expression profiling. 
    5.2 Expression microarray data analysis 
The HT 2.0 arrays were first scanned using a GeneChipR 3000 Scanner (7G upgrade) to 
capture images (DAT files). The raw data from the DAT file is converted to CEL files (based 
on intensities). ITERPLIER normalization was used to generate the CHP file. The outcomes 
from microarray analysis were ﬁrst uploaded into Qiagen’s Ingenuity pathway analysis (IPA) 
system for core analysis. IPA is a bioinformatic tool, which can analyse the gene expression 
patterns using a build-in scientiﬁc literature based database. IPA was performed to provide 
some new knowledge and identify signalling pathways, diseases and functions, and gene 
networks that are most signiﬁcant to microarray outcomes and to categorise diﬀ erentially 
expressed genes in MDS. In case of mutations, the gene expression in MDS patients with the 
mutant was compared with that of healthy donors. Heatmap analysis was used to demonstrate 
the expression patterns of these diﬀ erentially expressed genes. The data was filtered using IPA 
p value ≤0.05 to create a list of significantly up or down regulated pathways.  
5.3 Results  
5.3.1 Gene Expression profile of the healthy donors 
Ingenuity Pathway Analysis (IPA) highlighted several gene sets that are significantly down 
regulated or up-regulated in T-conv cells in HD (Table 5-1).  
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Table 5-1: Genes that are downregulated and upregulated in the T-conventional health donors 
 
The most significant gene sets that are down- and upregulated were compared between CD46 stimulated vs. 
unstimulated in the Tconventional health donors.  
 
The heatmap in Figure 5-1 shows a comparison of the significantly overexpressed genes 
between CD46 stimulated vs. unstimulated cells (p< 0.05). 
 
Figure 5-1: Heatmap depicting up-regulated and down-regulated genes in healthy donors 
Heatmap of the topmost up-regulated and the topmost down-regulated genes in Tconv cells from anti-CD3+CD46 
stimulated (n = 2) vs. unstimulated (n = 2) healthy controls, as determined by micro-array analysis. Expression levels 




The network analysis for CD46 stimulated versus unstimulated Tconv cells in HD was 
created, the data were normalised and the genes that were upregulated identified. IPA 
software was used to analyse the data (QIAGEN Bioinformatics). There were several 
activation signalling pathways (highlighted in red) that were significantly upregulated after 
stimulation with CD46 (Figure 5-2) and these included the genes below in the Table 5-2 with 
their corresponding p-values (all p-values are adjusted p-value to account for false discovery 
rate). 
Table 5-2: Upregulated pathways after anti-CD46 stimulation in healthy donors 
 
Gene name FDR q-value 
Complement system 5.26 ×10
-2
 
PI3K/AKT signalling 5.28 ×10
-2
 
PAK signalling 2.18 ×10
-2
 
Tec Kinase signalling 4.08 ×10
-2
 
























Granulocyte adhesion and diapedesis 3.40×10
-2
 
Agranulocyte adhesion and diapedesis 3.06×10
-2
 
Agrin interactions at neuromuscular junction 3.80×10
-2
 
Regulation of actin-base of motility by Rho 5.75×10
-2
 












Of the above activation signalling pathways the ones with the highest adjusted p-values were have been shown in 
bold. The complement system and the PI3K/AKT signalling pathway which were also upregulated have been 
discussed in the previous chapters, which are also of importance to this thesis. 
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Figure 5-2: The activation signaling pathways in the Tconventional health donors. 
The most significant activation signaling pathways (highlighted in red) were increased by anti-CD46 stimulation in Tconventional healthy donors. 
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IPA of the functions of these genes (Figure 5-3) showed that they are possibly involved in 
increasing the activity of T-cells movement, proliferation, infiltration, development and 
migration. The stimulation with anti-CD3+CD46 increased the expression of the following 
genes: BCL2L11, CFH, PM2, PLA2G10, ITGA3, TNSFSF10 and MAP2K4 (highlighted in 
red), but decreased the expression in CD6 and C5aR1 (highlighted in green). The reduction of 
C5aR1 after anti-CD3+CD46 stimulation inhibited T-cells development, cellular infiltration 
and the cell proliferation as shown by the dotted blue lines. Of the genes that were increased 
after anti-CD3+CD46 stimulation, CFH inhibited cellular infiltration, while TNFSF10 
inhibited both the cellular infiltration and proliferation of T-cells. On the other hand, PM2 
enhanced the T-cells proliferation (shown by the doted orange lines); MAP2K4 enhanced T-
cells development and proliferation; ITGA3 enhanced both T-cells movement and migration 
while PLA2G10 led to an enhanced T-cells movement, cellular infiltration and migration. 
Both BCL2L11 and CD6 which were increased and decreased respectively had no functional 




Figure 5-3: Significant genes functions of Tconv cells in HD.  
The stimulation of Tconv cells with anti-CD3+CD46 vs unstimulated cells resulted in increased BCL2L1, CFH, PM2, PLA2G10, ITGA3, TNSFSF10 and MAP2K4 (highlighted in red) and 
decreased CD6 and C5aR1 (highlighted in green). Stimulated functions marked by orange and the inhibiting actions in blue. 
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5.3.2 Differences between MDS and HD donors after anti-CD46 stimulation in 
T conventional cells  
In MDS vs HD after anti-CD46 stimulation of T conventional cells, IPA showed significant 
up-regulation in T-conventional cells for 10 genes whiles 4 genes were downregulated as 
listed in Table 5-3.  
Table 5-3: Genes that are downregulated and upregulated in the T-conventional in MDS vs HD 
after anti-CD46 stimulation. 
 





Anti-CD46 stimulated MDS 


















The heatmap in Figure 5-4 shows a comparison of the significantly overexpressed genes 
between CD46 stimulated in HD (n=2) vs MDS patients (n=3). It can be seen that the genes 




Figure 5-4: Heatmap depicting up-regulated and down-regulated genes in anti-CD3+CD46 
stimulation in MDS vs HD. Heatmap of the topmost up-regulated and the topmost down-regulated genes in 
Tconventional cells from anti-CD3+CD46 MDS (n = 3) vs anti-CD3+CD46 HD (n = 2), as determined by micro-
array analysis. Expression levels were listed in order of significance (P<0.05). Higher levels of expression are 
displayed in red and the lower levels in green. 
 
In the top signalling pathways, rheumatoid arthritis pathway and Triggering receptor 
expressed on myeloid cells 1 (TREM-1) pathway came out to be the top two most significant 
pathways in MDS patient after anti-CD3+CD46 stimulation (Figure 5-5 and 5-6). 
In the rheumatoid arthritis pathway of MDS patients there was reduction in four downstream 
molecules (NF-kB, IL-23 which polarized towards Th17, antigen presentation (TLR and MHC 
II) and Fas receptor (also known as an apoptotic antigen) compared to HD. The reduced IL-
23 pathway could potentially prevent polarisation toward Th17 phenotype while reduced Fas 
receptors expression also suggests that MDS cells do not undergo apoptosis as their 
respective ligand would be unable to bind to any receptor. This may suggest that MDS 
patients’ T-cells after anti-CD3+CD46 stimulation although may not go through FAS 
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mediated apoptosis, however, cannot proliferate and may not polarised toward Th17 cells as 
is the case in HD (Figure 5-5). 
In the TREM-1 signalling pathway there was a reduced expression of NF-kB, TLR and an 
increased expression of NLR, Caspase 1 and 5. NF-kB is important in secretion of 
proinflammatory cytokines, hence a reduction of these genes will cause a reduction in the 
associated downstream cytokines. TLR reduction will also potentially affect the secretion of 
the following cytokines TNF-α, IL-β, IL-6, IL-10 and GM-CSF in MDS patients compared to 
HD. Increased expression of NLR and Caspase (inflammasome pathway) will possibly lead to 
increased inflammasome activity which may contribute to the proliferation pressure and 




Figure 5-5: Rheumatoid arthritis pathway in MDS patients 
The molecules in green are the significantly reduced ones in MDS patients compared to HD. 
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Figure 5-6: TREM1 pathway in MDS patients’ vs healthy donors after anti-CD3+CD46 stimulation. 




A method to predict the upstream regulators and their target molecules revealed that several 
of them were significantly reduced in MDS patients compared to HD after anti-CD46 
stimulation (Figure 5-7) (Table 5-4), of which the three main regulators that are involved in 
MDS include FOXO1, POU5F1, STAT5a /b3. In a normal expression POU5F1 inhibits 
CASP1 and CASP6 (in red) but in its reduced expression it appears to have instead inhibited 
and reduced FAS, PYCARD and PAMAIP1 expression; this however, resulted in increased 
CASP1 and CASP6. STAT5a/b is another possible regulator that did not change significantly 
but at the same time it had an increase effect on WDR3, PDE4B and MAF. Also, a marginal 
change in FOXO1 may possibly lead to an increase and decrease expression of CCL20 and 
PAMAIP1 respectively. 
 




Target molecules p-value 
overlap 
RB1 CASP6, FAS, MAF, RRM2 0.000717 
CD3 BCL6, CCL20, CCR4, CD74, FAS, MAF, PDE4B, 
TLR2 
0,000724 
RELB CIITA, NFKB2 0,00233 
REL CIITA, NFKB2, PMAIP1 0.00244 




CASP1, CCL20, IL23A 0.00919 
POU5F1 BNIP2, CASP1, CASP6, FAS, PMAIP1, PYCARD 0.0152 
STAT5a/B MAF.PDEA4B, WDR3 0.0179 
FOXO1 CCL20, PMAIPI.SGK1 0.0179 
RELA CCL20, CIITA, NFKB2P, PDE4B, TLR2 0.018 
PRKACB PDE4B 0.02 




Figure 5-7: Effect of FOXO1, POU5F1, STAT5a /b3 on their target molecules. 
These three major upstream regulators were reduced in MDS patients compared to HD when 
stimulated with ant-CD46. 
 
5.3.3 Differences between MDS and HD donors after anti-CD46 stimulation in 
the presence of complement 
As shown above, anti-CD46 stimulation resulted in reduced NF-kB expression in MDS 
Tconv. I then wanted to assess the effect of adding complement components in addition to 
anti-CD46 to deduce whether it will improve NF-kB expression. Following this stimulation, I 
identified a few genes which were up or down regulated in MDS Tconv as shown in Figure 
5-8 and table 5-5. Nevertheless, these genes do not appear to have important function in T-
cells.  
However, by adding complement, NF-kB expression was rescued in MDS patients to levels 
similar to that observed in HD but the downstream effect on IL-17A pathway which is c-JUN 
and IkBzeta was reduced making this IL-17A pathway lower in MDS patient compared to HD 
(Figure 5-9).  
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Table 5-5: Genes that are downregulated and upregulated in the T-conventional in MDS vs HD 
after anti-CD46 plus complement stimulation. 
 
























Figure 5-8: Heatmap depicting up-regulated and down-regulated genes in anti-CD3+CD46 
stimulation with complement in MDS vs HD. 
Heatmap of the topmost up-regulated and the topmost down-regulated genes in Tcon cell from MDS 
(n = 3) vs HD (n = 2), as determined by micro-array analysis. Expression levels were listed in order of 
significance (P<0.05). Higher levels of expression are displayed in red and the lower levels in green. 
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Figure 5-9: Signaling pathway in MDS patients’ vs healthy donors after anti-CD3+CD46 stimulation with complement.  




In this chapter, microarray has been applied to identify diﬀ erentially expressed genes in the 
MDS vs HD after stimulation with anti-CD46 in the presence or absence of C3a+C5a 
treatment. I have used IPA analytical approach to investigate the differential gene expression 
profiles of T-cells in MDS and HD. The inﬂammation and immune response, cytokine 
signaling, cellular growth and movement and function, were signiﬁcantly activated suggesting 
their critical roles in MDS.   
I compared the gene expression of anti-CD46 stimulation vs unstimulated Tconv cells in HD. 
I found that DARS, TCP1 and RUNX3 were upregulated when cells were stimulated with anti-
CD46 while genes such as MIR3675 and MIR4446 were downregulated. In relation with the 
findings and discussions in the previous chapter I found that the complement system and the 
PI3K/AKT signalling pathway may have a role in upregulating Tconv cells after stimulation 
with anti-CD46.  
CD46 has a role in T-cell function by upregulating and downregulating some genes that have 
downstream effect on T-cell proliferation, migration and development and infiltration and 
movement. For example, decreased C5aR1 has been shown to affect T-cell development, 
infiltration and proliferation. 
The possible differences in gene expression between HD and MDS patients were investigated 
in this chapter. After anti-CD3+CD46 stimulation, two major pathways, the rheumatoid 
arthritis and Triggering receptor expressed on myeloid cells-1 (TREM-1) pathways were 
detected and signiﬁcantly activated. In the rheumatoid arthritis pathway of MDS patients 
there was reduction in four downstream factors/molecules: NF-kB, IL-23, antigen presentation 
(TLR and MHC II) and Fas receptor (also known as an apoptotic antigen). NF-kB has a major 
role in many downstream effects such as the induction or proinflammatory cytokines and 
enhancement of apoptosis. Increased activity of NF-kB has been shown in MDS (Okubo et 
al., 2017, Kerbauy et al., 2005). A decrease in NF-kB following anti-CD46 stimulation 
suggests that all the downstream effects such as cytokine induction and apoptosis may be 
impaired. Several reports show that NF-κB inhibition may be a useful therapeutic target in 
tumour cell death or growth inhibition (Braun et al., 2006, Breccia and Alimena, 2010). Here, 
I have shown that despite stimulation with anti-CD46, MDS T-cells do not upregulate their 
NF-κB expression which prevent proliferation and impaired their function.  
The reduced IL-23 pathway could potentially prevent polarisation toward Th17 phenotype 
while reduced Fas receptors expression also suggests that MDS cells do not undergo 
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apoptosis as their respective ligand would be unable to bind to any receptor. This may suggest 
that MDS patients’ T-cells after anti-CD3+CD46 stimulation although may not go through 
Fas mediated apoptosis, however, cannot proliferate and may not polarised toward Th17 cells 
as is the case in HD. A reduction in Fas receptor expression by anti-CD46 stimulation may 
suggest that in MDS patients there is the potential for reduced apoptosis as receptor-ligand 
interactions may be impaired. 
Similar to what was observed in the rheumatoid arthritis pathway, there was a reduction in 
NF-kB expression in the TREM-1 signalling pathway. Engagement of TREM-1 binding to its 
receptor (although unknown) amplifies the Toll-like receptor (TLR)-initiated responses to 
microbes and triggers the downstream synthesis of pro-inflammatory cytokines. It is therefore 
possible that the reduced TLR expression will impair the TREM-1 pathway and affect its 
downstream induction products. Engagement of TLRs by their specific ligands leads to the 
activation of transcription factors that cooperatively regulate the expression of IFNs and other 
pro-inflammatory cytokines and chemokines (Ganan-Gomez et al., 2015). Between 40–80% 
of MDS patients have been shown to have overexpressed levels of certain TLR and their 
signal transducers (Maratheftis et al., 2007, Kuninaka et al., 2010) and hence the inhibitory 
action of anti-CD46 on TLR is a very significant finding as this may lead to under expression 
of multiple TLR downstream signalling mediators such as the secretion of the following 
cytokines TNF-α, IL-β, IL-6, IL-10 and GM-CSF.  
An increased expression of NLR, Caspase 1 and Caspase 5 following anti-CD46 stimulation 
may lead to increased inflammasome activity and an increased IL-1β secretion. Finally, only 
Interleukin-17A (IL17A) signaling pathway in MDS patients’ vs healthy donors after anti-
CD3+CD46 stimulation with complement (C3a+C5a) treatment is signiﬁcantly activated. It 
showed the importance of complement in rescuing NF-kB expression in MDS patients 
following anti-CD46 stimulation which may improve T-cell function in these patients and 
restate an effective immune-surveillance.  
5.5 Perspective 
For future work it is important to employ additional techniques such as DAVID, Gene-mania, 
KEGG and other gene ontologies analytic tools to look for connections/pathways as these 
have been shown to give a better understanding of the statistical significance of the pathways. 
Gaining a better understanding of the basic nature of the MDS by determining critical 
molecular differences between MDS and HD samples helps accelerate the identification of 
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drug targets and diagnostic or prognostic markers. Our results may help to illuminate the 
molecular aspects of MDS and to develop potential therapeutic targets of the disease. Thus, 
creating new treatment paradigms targeting these networks in their entirety, rather than single 
proteins, could be necessary for controlling and treating MDS.  
5.6 Limitations 
The main limitation of this study is the limited number of participants in each subgroup. 
Although as expected, the statistical power was reduced due to the small number of samples, 
these findings could be used in future research on higher number of patients.  
Replicating these findings in a larger study is an important future step. Furthermore, the 
limited sample size probably leads to inflated p-value; therefore it is hard to draw a definitive 
conclusion on the implicated pathways and genes in our study. A replication using a bigger 
study is essential using qPCR, targeted sequencing techniques such as MySEQ or PcBio and 












Chapter 6. The General Discussion, Future Studies and 
Limitations 
 
6.1 General Discussion  
The complement system is one of the oldest known systems involved in defence against 
pathogens. It can be activated by pathogen-associated or danger-associated molecular patterns 
leading to the cleavage of the complement components C3 and C5 into the respectively 
anaphylatoxins C3a and C5a, as well as the generation C3b and C5b, both opsonins, all of 
which play various roles in innate immune response and activation of the adaptive arm of the 
immune system.  
Intracellular complements such as C5a through C5aR2 mediated TGF-β pathway, and C5a 
through C5aR mediated mTOR pathway play a role in driving CD4
+
 T-cells toward either a 
regulatory or effector phenotypes. Although these complement components and their 
receptors (C3aR, C5aR1 and C5aR2 (C5L2)) play essential roles in innate and adaptive 
immune responses, their contribution in priming CD4
+
 T-cells in patients with MDS is not 
clear.  
Considering the importance of T-cells and the role of complement in the immune response to 
pathogens and other haematological malignancies, this work was carried out to investigate the 
potential role of intracellular complement components C3a and C5a, regulator CD46 and their 
receptors C3aR, C5aR1 and C5aR2 in inducing CD4
+
 T-cell polarisation and function in 
MDS patients. To do this I investigated whether there are differences between MDS and HD 
in terms of intracellular and surface complement receptors (C3aR, C5aR1 and C5aR2) and 
complement component (C3a and C5a) and if so, any differential expression between LR and 
HR-MDS disease.  
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Furthermore, any potential differences between HDs, LR and HR-MDS in response to 
complement pathway activator (mainly CD46), a well as the main signalling pathways for 
polarising CD4
+
 T-cells including mTOR, and TGF-β signalling and associated proteins were 
investigated following stimulation with anti-CD46 in both HDs and MDS patients. Finally, I 
identified additional three pathways which may be differentially expressed in T-cells from 
MDS patients compared to HDs following Tconv and Tregs stimulation with anti-CD46 (with 
or without complement components). 
In order to achieve this I optimised a protocol in which the PBMCs from the HD were 
cultures at four different time points (1min, 1hr, 24hr and 48hr) in the presence (test) or 
absence (control) of anti-CD3±CD46, and the expression of surface and intracellular 
complement receptors (CD46, C3aR, C5aR1 and C5aR2) assessed using flow cytometry. The 
24-hr time point was shown to be the optimum for this study. 
The data suggest that intracellular expression of CD46 in both LR and HR-MDS patients 
were lower than in HD. Lack of available intracellular complement components in MDS T-
cells, subsequent lack of signalling through C3aR and C5aR along with upregulation of 
C5aR2 (C5L2), an alternative receptor for C5a, in MDS patients may contribute in the T-cell 
dysfunction and lack of polarisation toward Th1 or Th17. Moreover, the contribution of C5L2 
in regulating pro-inflammatory and anti-inflammatory responses and, in particular, certain 
features of the complement signalling pathway, makes it a possible agent for remedying 
diseases such as MDS.  
I have also investigated the potential changes in TGF-β signalling pathway proteins as well as 
mTORc following stimulation with anti-CD46 antibody. The data demonstrated that the 
mTORc protein level in HR-MDS is reduced and does not change in response to complement 
components or to receptor stimulation, and neither do the level of Akt. This may prevent 
CD4
+
 T-cells polarizing towards pro-inflammatory T-cells (Th1 or Th17) therefore averting 
an effective immune-surveillance against malignant clones.  
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Lack of response to complement related co-stimulation and increase in C5aR2 (C5L2) 
expression indicate a potential mechanism for Treg expansion in MDS. Overexpression of 
pro-inflammatory cytokines is strongly associated with LR-MDS. Moreover, these data show 
that complement components may modulate cytokine and chemokine-induced differentiation 
and activation of CD4
+
 T-cells, possibly through TGF-β regulation.  These findings may lead 
to identification of new therapeutic targets in MDS, although need further studies on larger 
cohort of patients. 
The gene expression profile of Tconv following stimulation with anti-CD46+/- complement 
components has been studied next. Two major pathways, the rheumatoid arthritis and TREM-
1 pathways were found significantly activated and different between MDS and HDs. In the 
rheumatoid arthritis pathway of MDS patients there was reduction in four downstream 
factors/molecules (NF-kB, IL-23, antigen presentation (TLR and MHC II) and Fas receptor. 
Anti-CD46 stimulation also fails to induce IL-23 pathway in MDS T-cells, a pro-
inflammatory cytokine that is essential for the survival of IL-17 producing effector cells 
I observed a reduced Fas receptors expression upon anti-CD46 stimulation. Similarly to what 
was observed in the rheumatoid arthritis pathway, there was a reduction in NF-kB expression 
in the TREM-1 signaling pathway. An increased expression of NLR, Caspase1 and Caspas5 
following anti-CD46 stimulation will lead to increased inflammasome activity and an 
increased IL-1β secretion.  
Finally, this works shows the potential importance of complement in CD4
+ 
T-cells 
polarisation in MDS and this is the first time that this has been investigated and shows 
encouraging data which would need to be continued in more detail to elucidate the pathway(s) 
that leads to the lack of complement in T-cells of MDS patients and also identify potential 
molecules involved which can serve as potential therapeutic targets in MDS in the future.  
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6.2 Future studies 
The role of complements receptor especially C5L2 in the different subclasses of MDS 
patients and other results obtained in this thesis raised some prospects which can be addressed 
in future studies. A consistent theme throughout the thesis work was the emphasis on 
studying the dynamics of biological processes on complement treated T-cells from MDS 
patients compared to HDs. As suggested by the results, a further direction would be to expand 
the study and perform deep phenotyping of CD4
+
 T-cells following the proposed conditions 
to identify specific subsets of Tregs and T conv which may be affected/polarised in HDs and 
or MDS patients. This PhD thesis provides a foundation upon which these other works can be 
built.  
Some of the experiments that I will undertake to support this initial evidence include: 
1- Blocking C5L2 with anti-C5L2 blocking mAB to determine whether this receptor is 
directly involved or not. This will also help to elucidate whether the unusual effects 
of C5L2 in MDS are reversed or not. 
2- Using different concentrations of complement components (C3a+C5a) to understand 
how that changes the fate of T-cells. 
3- Blocking upregulated pathways using particular molecules and confirming the up- 
and down regulating pathway at protein levels by employing Western blot or Flow 
cytometry. 
4- The gene expression pathways need for biological testing to test the predictions (test 
the findings biologically (e.g, qPCR, sequencing and in vitro experiments for 
confirmation of up/down regulated genes). 
5- To employ additional techniques such as DAVID, Gene-mania, KEGG and other 
gene ontologies analytic tools to look for connections/pathways as these have been 
shown to give a better understanding of the statistical significance of the pathways.  
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6- A fundamental issue to address is whether activated T-cells following complement 
pathway stimulation could reject malignant clones both in-vitro and in-vivo. Using 
the established in-house NSG and NSG-SGM3 mouse models will help to address 
this question.  
7- The GEP data suggests another interesting aspect to be investigated, which is to 
identify genes which could potentially be targeted for therapeutic purpose and restore 
an effective immune response in MDS patients. 
6.3 Limitations 
1- In experiments where purified cell fractions were not used there could be the 
possibility of heterogeneous within the different cell populations from the different 
patient types (LR-, HR-MDS and healthy donors) thereby making comparability 
between the different subsets difficult.   
2- It was evident that some of the results of T-cell stimulation experiments showed that 
the response of HR-MDS samples were more closely to that of normal donors than 
that of LR-MDS samples. It is therefore possible that these may reflect more as 
features of LR-MDS (e.g. cytopenias) rather than potential mechanisms of 
progression. 
3- I concede that the sample sizes for the different patient types used in this thesis were 
very small. Any future work will take this into account and increase the numbers to 
enable greater statistical power. Any future experimental approaches will be largely 
based on gene expression approach.  
4- Most of the genes have unknown functional background information thereby making 
more difficult to provide a more in-depth explanation of the findings of the data. One 
solution will be to perform gene sequencing and to increase the sample size to 
increase the statistical power. 
5- Obviously, funding was also a major challenge. However, this preliminary data can 




Intracellular CD46, C3aR and C5aR1 expression 
 
Figure 3-S1. Intracellular MCP (CD46) expression on human Tregs cells.  
Cells were activated for 24 h with an anti-CD3, anti-CD3±CD28 and anti-CD3±CD46 antibody. Intracellular 
CD46 expression in Tregs was measured at the indicated time point. The results are representative of thirty (n=30) 
experiments and the data show mean ± SD derived from healthy donor (n=10), low-risk MDS (n=10) and high-risk 
MDS (n=10) experiments.  
 
Figure 3-S2. Expression of intracellular C3aR in human Treg cells by flow cytometry analysis 
(FACS).  
PBMCs were grown in 48-well plates and activated with an anti-CD3 (2.0 μg/ml) ± CD28 (3.0 μg/ml) or CD3 (2.0 
μg/ml) ± CD46 (2.0 μg/ml) for 24 h. Intracellular C3aR expression was measured in Treg cells and data show the 
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Figure 3-S3. Intracellular C5aR1 participate in human Treg cells FACS 
Results show flow plots of PBMCs which were non-activated or activated for 24 h with an anti-CD3, anti-
CD3±CD28 or anti-CD3±CD46 antibody. Treg intracellular C5aR1 expression was measured at indicated time 
point. The data show the mean ± SD derived from healthy donors (n=10), low-risk MDS (n=10) and high-risk 
MDS (n=10) experiments (plots are representative of a total of 30 experiments (n=30).  
 
Intracellular CD46 and C5L2 expression in human Tconv cells 
 
Figure 3-S4. Intracellular CD46 expression in human Tconv cells using FACS analysis. 
PBMCs were cultured in 48-well plates and then stimulated with mAbs anti-CD3, anti-CD3±CD28 or anti-
CD3±CD46 antibodies. Intracellular CD46 expression in Tconv cells was monitored at 24 h. The data show mean 
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Figure 3-S5. Intracellular expression of C5L2 in human Tconv cells using FACS analysis. PBMCs 
were activated for 24 h with mAbs anti-CD3, anti-CD3±CD28 or anti-CD3±CD46 antibodies. Intracellular C5aR2 
(C5L2) expression in healthy donor, low-risk-MDS and high-risk MDS Tconv cells was measured at different time 
points by FACS analysis. The data show the mean ± SD derived from healthy donor (n=10), low-risk MDS (n=10) 
and high-risk MDS (n=10) experiments.  
 
Expression of CD46 and C5aR1 on the surface of Treg 
 




T-cells using flow-cytometry 
analysis (FACS). 
PBMCs were cultured in 48-well plates and then stimulated with mAbs anti-CD3, anti-CD3±CD28 or anti-
CD3±CD46 antibodies. Surface CD46 expression of T-cells (Treg) was monitored at 24 h. The data show the 
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Figure 3-S7. Expression of C5aR1 on the surface of Tregs. 
PBMCs were activated for 24 h with an anti-CD3±CD46 antibody. C5aR1 expression on the surface of Treg cells 
was measured at 24 h. The data show the mean ± SD derived from ten experiments (n=5) for each group.  
 
Expression of C3aR on the surface of Tconv 
Figure 3-S8. Expression of C3aR on the surface of human Tconv cells by flow cytometry analysis 
(FACS).  
PBMCs were grown in 48-well plates and activated with an anti-CD3 (2.0 μg/ml) ± CD28 (3.0 μg/ml) or CD3 (2.0 
μg/ml) ± CD46 (2.0 μg/ml) for 24 h. C3aR expression was measured on the surface of Tconv cells and the data 
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Figure 4-S1. pAKt levels expression in human naive CD4
+
 T-cells.  
Naïve CD4+ T-cells from healthy donor, low-risk MDS and high-risk MDS were left inactivated or                           
activated for 24 h with mAbs anti-CD3, anti-CD3±CD28 or anti-CD3±CD46 antibodies and cells were untreated 
or treated with 50nM C3a and C5a for each. The data show the mean ± SD derived from healthy donor (n=6), low-
risk MDS (n=6) and high-risk MDS (n=6) experiments. Data are representative of six experiments with similar 
results.  
 
Figure 4-S2. pERK1/2 levels expression in human naive CD4
+
 T-cells.  
CD4+ T-cells, from healthy (n=6), low-risk MDS (n=6) and high-risk MDS donors (n=6) without (−) or with (+) 
stimulation (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with presence (+) of 50nM C3a and C5a for 






























































































































































































































































































































































































































































































































































































































































































































Figure 4-S3. The levels of TGFbRII 
Naïve CD4+ T-cells isolated from PBMCs of healthy (n=6), low-risk MDS (n=6) and high-risk MDS (n=6) donors 
without (−) or with (+) stimulation (anti-CD3/28) or (anti-CD3/46) and with absence (−) or with presence (+) of 
50nM C3a and C5a for each. Error bars indicate SD of six experiments. Data are representative of six experiments 
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Background: T cell-mediated immune 
dysregulation is an important feature of 
myelodysplastic syndrome (MDS). The 
expansion of regulatory T cells (Tregs) is 
one of the important factors in the 
progression of intermediate/high-risk MDS 
to acute myeloid leukemia. However, the 
exact mechanism for the expansion of 
Tregs in MDS is unknown. Intracellular 
complements (particularly C3a and C5a) 
play a crucial role in the polarization of 
CD4+ T cells toward regulatory or effector 
phenotypes through TGF-β pathway 
(C5aR2 mediated) or mTOR (C5aR1 
mediated) respectively.  
The Role of Intracellular Complement in the Induction of Ineffective CD4+ T Cell 
Mediated Immune Responses in Myelodysplastic Syndrome (MDS) 
 
Aim: The main aim of this project was to 
invest igate the potent ia l ro le of 
intracellular complement system in 
polarisation and function of CD4 + T cells 
in MDS.  
 
Result: 
Figure 3: The role of complements components 
in levels of mTOR and TGF- β signalling 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4: Cytokine secretion in response to 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































P* = 0.0428 
P* = 0.0352 
P***= 0.0008 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2: Upregulated signalling pathways after 
anti-CD46 stimulation in healthy donors 
Figure 6: Rheumatoid arthritis pathway in MDS patients 
Figure 8: Signaling pathway in MDS patients’ vs healthy donors 
after anti-CD3+CD46 stimulation with complement.  
Conclusion:  
Altogether, this work shows for the first time the potential 
role of complement in CD4 + T cells polarisation in MDS 
patients and provides data on two major pathways that 
may be implicated in the lack of complement in T cells of 
MDS patients. Future work to explore these further may 
help to identify potential molecules involved which can 
serve as potential therapeutic targets in MDS in the future. 
Figure 2: Western Blot analysis for Complement 
Components (C5a)  and (C3a) 
Figure 5: Significant genes functions of Tconv 
cells in HD 
Table 1: Summary of the results of intracellular 
and surface staining of complement receptors 
in Tregs and Tconv cells  
↑ is high; ↑↑ is significantly higher; → is 
similar levels; HD: healthy donors; HR: high 
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Figure 1: CD46 activation on high-risk MDS Treg 
cells induces intracellular C5L2 upregulation 
Authors: Dr. Samia T. Al-Shouli1*2, Dr. Shahram Y. Kordasti1, Professor Ghulam J. Mufti1 
1 King's College London (KCL) and King's College Hospital (KCH), London, United Kingdom 
2 King Saud University (KSU) and King Khalid University Hospital (KUH), Riyadh, Kingdom of Saudi Arabia 
Copyright © 2018  
Dr. Samia AL-Shouli  
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Figure 7: TREM1 pathway in MDS patients’ vs healthy donors after 
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Background: Myelodysplastic syndrome (MDS) is a relatively 
uncommon clonal haematological disease that is characterised by 
peripheral blood cytopenias despite a normal or hypercellular bone 
marrow. The disease which is common in the elderly transforms to 
acute myeloid leukaemia in up to 40% of cases. Several studies have 
established that the T-cell mediated immune dysregulation is an 
important feature of MDS. Low risk MDS is associated with a 
proinflammatory environment and an increase in IL-17 producing T-
cells as well as an increase in the serum IL-17, IL-12, RANTES and 
IFN-γ. In contrast, IL-10 (inhibitory factor) and IL-2R (soluble receptor) 
are increased in high risk MDS. A high number of IL-17 producing 
CD4+ T-cells are found in low risk MDS compared to the high-risk 
disease where expansion of T regulatory cells (Tregs) is the main 
feature. However, the mechanism for this switch in the immune 
signature is not fully understood. Immune cell derived complement 
activation fragments are recently identified as key players in driving 
and modulating adaptive immunity, C3a and C3b. C3 fragments C3a 
and C5a are particularly important in induction of IFN-γ secretion 
through autocrine engagement of the C3a receptor and CD46 (C3b 
receptor). The activation pathway following CD46 activation varies 
between Tconv and Tregs and the balance between these pathways is 
crucial for the Treg/Tconv equilibrium. The objective of this study was 
to elucidate the role of intracellular complement components (C3a and 
C5a), regulators (CD46) and their receptors (C3aR, C5aR1 and 
C5aR2) in the expansion of T regulatory cells, which is one of the main 
factors in the progression HR MDS patients towards AML.  
Comparative study of Complement Components, Regulators and 
Receptors in Healthy Donors vs. MDS Patients   
Result: Tregs were stimulated with anti-CD3+CD46 expressed a 
significantly higher level of intracellular C5aR2 in high-risk MDS 
compared to low-risk MDS (P=0.003) and healthy donors (P=0.0042). 
Thus, CD46 induced an upregulated C5aR2 expression of Tregs in 
high-risk MDS patients. Western blotting demonstrated that in healthy 
donors the stimulation of CD4+ T cells with anti-CD3+CD46 resulted in 
downregulation of both C5a and C3a compared to non-activated or 
anti-CD3+CD28 stimulation. In both high and low-risk MDS donors, 
there was no expression of these two complement components 
whether the cells were activated or non-activated. 
Figure 4. Western Blot analysis for Complement Components 
(C5a)  and (C3a) 
Table 1. Summary of the results of intracellular and surface 
staining of complement receptors in Tregs and Tconv cells  
↑ is high; ↑↑ is significantly higher; → is similar levels; HD: healthy 
donors; HR: high risk MDS; LR: low risk MDS. 
Figure 2. CD46 activation of Tconv in high-risk MDS upregulates 
the intracellular C3aR expression 
Authors: Dr. Samia T. Al-Shouli1*2, Dr. Shahram Y. Kordasti1, Professor Ghulam J. Mufti1 
1 King's College London (KCL) and King's College Hospital (KCH), London, United Kingdom 
2 King Saud University (KSU) and King Khalid University Hospital (KUH), Riyadh, Kingdom of Saudi Arabia 
Copyright © 201 8 Dr. Samia AL-Shouli samiashouli@yahoo.com    
Method: PBMCs and CD4+ T-cells from healthy controls (n=10), low-
risk (n=10) and high-risk MDS patients (n=10) were used for this study. 
Anti-CD3 (2.0 µg/mL), anti-CD28 (3.0 µg/mL) and/or anti-CD46 (2.0 
µg/mL) antibodies were used to stimulate cells or were deliberately left 
non-activated. Flow cytometry was used to monitor the intracellular 
expression of C3aR, C5aR1, C5aR2 (C5L2) and CD46 (C3b receptor), 
as well as their surface expression on T-conventional and Treg CD4+ 
T-cells. Western blot was used to evaluate C3a and C5a expression of 
cultured CD4+ T-cells. 
Figure 1. CD46 activation on high-risk MDS Treg cells induces 
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Figure 3. Post-CD46 activation of Tconv in high-risk MDS induces 
overexpression of intracellular C5aR1  
Conclusion: In this study, we observed no expression of C3a and C5a, 
subsequent lack of signalling through C3a and the C5a receptors, along 
with up-regulation of C5aR2 (an alternative receptor for C5a) in patients 
suggesting a potential mechanism for Treg expansion in MDS. 
Collectively, the results demonstrate that the insufficiency or excess of 
function and/or distribution of complement expression may partly 
contribute to inappropriate CD4+ T-cells activity in MDS and these 
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